Introduction {#s1}
============

The Notch signaling pathway mediates communication between neighboring cells in metazoans and thereby regulates a multitude of developmental processes in various tissues ([@bib2]; [@bib51]; [@bib4]; [@bib18]; [@bib39]; [@bib22]; reviewed in [@bib27]; [@bib23]). This communication depends on the interaction of Notch receptors on the surface of the signal receiving cells with transmembrane ligands on the surface of adjacent cells. Ligand binding then leads to a sequence of proteolytic cleavages of the receptor releasing the Notch intracellular domain (NICD) from the membrane. NICD translocates into the nucleus where it enters into a complex with a CSL protein ([C]{.ul}BF-1/RBPJ in mammals, [S]{.ul}uppressor of Hairless in flies, and [L]{.ul}ag-1 in worms) and a protein of the Mastermind family ([@bib37]; [@bib49]; [@bib32]; [@bib33]; [@bib48]; [@bib10]) to regulate transcription of target genes (reviewed in [@bib7]).

Mammals have four Notch receptors (N1-N4) and four activating ligands of the DSL ([D]{.ul}elta, [S]{.ul}errate, [L]{.ul}AG-2) family: DLL1 and DLL4, orthologs of *Drosophila* Delta, and JAG1 and JAG2, orthologs of *Drosophila* Serrate. DLL1 and DLL4 are similar in domain structure, size and sequence ([@bib45]). Both proteins contain an N-terminal MNNL (also referred to as C2) domain ([@bib9]; [@bib47]), followed by a DSL domain and eight EGF-like repeats in their extracellular portion, and a less well conserved intracellular domain. The MNNL and DSL domains, required for high-affinity binding of Delta-like ligands to Notch receptors ([@bib40]; [@bib13]), contact EGF repeats 12 and 11 of Notch, respectively ([@bib28]). Contributions from adjacent EGF-like repeats, however, are required for signal transduction by Delta-like ligands ([@bib1]) as well as for optimal interaction with Serrate ([@bib50]) and Jagged (JAG)-family ligands ([@bib29]). Although the biological activities of DLL1 and DLL4 are partially overlapping, the two proteins are not equivalent in vitro or in vivo. In cell culture studies, DLL4 is more effective than DLL1 in activating N1 signaling during T cell development ([@bib3]), consistent with its ten-fold higher binding affinity in binding studies using purified fragments of N1, DLL1, and DLL4 ([@bib1]). In vivo, studies of adult intestinal epithelium in mice have shown that DLL1 and DLL4 are co-expressed in crypts and act redundantly to maintain the intestinal stem cell pool ([@bib36]). In contrast, however, mouse DLL1 cannot fully replace DLL4 in its ability to trigger T lineage commitment ([@bib3]; [@bib30]). Conversely, endogenous DLL4 does not substitute for DLL1 in its ability to promote development of the arterial vascular epithelium ([@bib46]), nor does it compensate for the function of DLL1 in the paraxial mesoderm, a tissue where these ligands are normally not co-expressed: mice in which DLL1 was replaced by DLL4 had severe somite patterning defects and showed premature myogenic differentiation leading to reduced skeletal muscles. However, the function of DLL1 during early retina development was rescued by DLL4 in these mice ([@bib38]).

Collectively these studies indicate that the functionality of DLL1 and DLL4 strongly depends on context, but it remains unclear which portions of these similar DSL proteins account for their functional non-equivalence. A recent study in cell culture observed that DLL1 and DLL4 stimulate NOTCH1 receptors to produce responses with different dynamics, attributing differences between pulsatile signaling of DLL1 and sustained signaling by DLL4 to the intracellular, rather than the extracellular, regions of the proteins ([@bib34]). Here, we investigate the influence of the extracellular and intracellular regions of DLL1 and DLL4 chimeric proteins on ligand function in cell culture assays, and for selected chimeras, in biochemical binding assays and in vivo in mice. We observe that in vivo differences of DLL1 and DLL4 function during somite patterning and myogenesis are encoded by the ligands ectodomains, that DLL1 and DLL4 are able to discriminate between NOTCH1 and NOTCH2 in vitro, and that ligand residues outside of the known binding interface are important contributing factors for ligand function in vivo.

Results {#s2}
=======

The extracellular domain dominates ligand function during somitogenesis {#s2-1}
-----------------------------------------------------------------------

Previous in vivo analyses indicated that DLL4 cannot substitute for DLL1 function during embryonic development ([@bib38]). To test whether the inability of DLL4 to rescue the loss of DLL1 in the paraxial mesoderm in vivo resides in its extra- or intracellular domain we generated single copy transgenic mice allowing for the conditional expression of chimeric DLL molecules consisting of the extracellular domain of one ligand and transmembrane and intracellular domain of the other (D1*ECD*\_D4*ICD* and D4*ECD*\_D1*ICD*, II and VII in [Figure 1](#fig1){ref-type="fig"}). Transgenes were introduced into the *Hprt* locus of *Hprt*-deficient E14TG2a ES cells by homologous recombination using the strategy already employed for the initial analysis of full length DLL1 and DLL4 during somitogenesis ([@bib38]). Briefly, cDNAs encoding chimeric ligands were cloned into the targeting vector pMP8 in reverse orientation downstream of neomycin phosphotransferase (*neo^r^*) driven by the CAG promoter. Cre-mediated recombination of two *loxP* sites and two mutant *loxP2272* (*loxM*) sites removes the *neo^r^* cassette and flips the gene of interest and results in its expression from the CAG promoter ([Figure 2A](#fig2){ref-type="fig"}).

![Schematic representation of DLL1 and DLL4 and variant proteins.\
I-X, full-length and chimeric ligands generated by domain swaps. XI and XII, ligands with exchanges of the known NOTCH1 contact amino acids in the MNNL and DSL domains. XIII, DLL4 variant with an N109G mutation that eliminates the N-glycosylation site in DLL4. XIV-XVIII, soluble proteins encoding the N-terminal region up to and including EGF5 carrying a C-terminal Avi-His-tag for protein purification. I-XIII were tested in cell-based Notch activation assays, II, III, VII and XI in transgenic mice, XIV-XVIII used for measurements of binding affinities to N1. Proteins analyzed in cell-based assays were C-terminally Flag-tagged, proteins analyzed in mice were untagged. Break points and surrounding amino acid sequences and point substitutions are illustrated in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. Red domains/spikes: DLL1; blue domains/spikes: DLL4; white asterisks: N109G mutation. *ECD,* extracellular domain; *N*, N-terminus; *D*, DSL domain; *E*, EGF repeat, *TM*, transmembrane domain; *ICD*, intracellular domain; D, DLL; cont, N1 contact amino acids.](elife-40045-fig1){#fig1}

![The extracellular domains of DLL1 and DLL4 determine ligand behavior during somitogenesis.\
(**A**) Scheme of the targeting vector pMP8.CAG-Stop used to introduce inducible chimeric ligands into the *Hprt* locus, and of Cre-mediated activation of transgene (D1*ECD*\_D4*ICD* or D4*ECD*\_D1*ICD*) expression driven by the CAG promotor (*CAG* prom). 5' hom and 3' hom, *Hprt* 5' and 3' homology regions; ex1-3 (grey boxes), *Hprt* exons; *neo^r^*, neomycin phosphotransferase; *pA*, polyadenylation signal; *hHPRT* prom, human *Hprt* promoter; *DLL1/4iresdsRED*, chimeric ORF--linked to dsRed tag by an internal ribosomal entry site (IRES). (**B**) *Uncx* expression in E9.5 wild type embryos (a, a'; n = 28), embryos lacking DLL1 in the mesoderm (b, b'; n = 12) and male embryos lacking DLL1 in the mesoderm that express either D1*ECD*\_D4*ICD* (c, c'; n = 9) or D4*ECD*\_D1*ICD* (d, d'; n = 8) showing that the extracellular domain of DLL1 but not of DLL4 can restore *Uncx* expression. (**C**) Whole mount immunofluorescent staining of wild type (**a--c**) and *D4ECD_D1ICD/Y;T(s):Cre* (**d--f**) PSMs using antibodies recognizing the extracellular domain of DLL4 showing co-localization of the exogenous chimeric ligand with pan-Cadherin (panCad) at the cell surface. Additional intracellular staining most likely reflects the presence of the ligand in the ER and trans Golgi as observed previously for DLL1 in cultured cells ([@bib17]; [@bib31]) and for endogenous DLL1 and transgenic DLL4 in the PSM ([@bib38]). n = 3 for wild type, n = 4 for *D4ECD_D1ICD/Y;T(s):Cre*; Scale bar = 10 µm.](elife-40045-fig2){#fig2}

To test whether the extracellular or intracellular domain determines the inability of DLL4 to rescue the loss of DLL1 in mesodermal tissues of early embryos, we induced expression of either chimeric ligand and simultaneously removed endogenous DLL1 using a floxed *Dll1* allele and a Cre transgene expressed in the primitive streak driven by a promoter derived from *brachyury* (*T(s):Cre*) ([@bib16]). Because the *Hprt* locus is located on the X-chromosome, we used hemizygous male embryos for the analysis. As previously described, inactivation of *Dll1* in the mesoderm resulted in loss of *Uncx* (formerly called *Uncx4.1*) expression in caudal somite compartments (n = 12; [Figure 2Bb,b\'](#fig2){ref-type="fig"}) indicating severe somite patterning defects compared to wild type embryos (n = 28; [Figure 2Ba,a\'](#fig2){ref-type="fig"}). Expression of D1*ECD*\_D4*ICD* in *Dll1*-deficient embryos (n = 9) restored robust expression of *Uncx* similar to full length DLL1 ([@bib38]). *Uncx* expression expanded into cranial somite compartments ([Figure 2Bc,c\'](#fig2){ref-type="fig"}) reminiscent of ectopic Notch activity ([@bib16]), probably reflecting non-restricted D1*ECD*\_D4*ICD* expression throughout the PSM and somites. In contrast, expression of D4*ECD*\_D1*ICD* barely restored *Uncx* expression in the majority (n = 8/12) of *Dll1*-deficient embryos ([Figure 2Bd,d\'](#fig2){ref-type="fig"}), a phenotype similar to that seen with full-length DLL4 ([@bib38]), even though the chimeric ligand was expressed and detected on the cell surface of PSM cells ([Figure 2Cd-f](#fig2){ref-type="fig"}). As observed previously for full-length DLL4 ([@bib38]) some embryos (n = 4) displayed essentially normal *Uncx* expression (not shown), which might result from some perdurance of DLL1 activity or delayed or inefficient excision of endogenous *Dll1*. Overall, this analysis strongly suggests that the functional difference between DLL1 and DLL4 observed in vivo during somitogenesis resides in the extracellular domains.

Regions outside the known receptor binding domain are essential for full DLL1 function in vivo {#s2-2}
----------------------------------------------------------------------------------------------

The N-terminal MNNL and DSL domains and adjacent EGF repeats 1--3 constitute the major interface for interaction between DSL ligands and Notch receptors, and are essential for (full) activation of Notch signaling ([@bib13]; [@bib1]; [@bib28]; [@bib43]; [@bib29]). To analyze whether this region accounts for the observed differences between DLL1 and DLL4 in vivo we generated a chimeric ligand that contained the N-terminal region up to and including EGF3 of DLL1 fused to EGF4 and the remaining C-terminal portion of DLL4 (D1*N-E3*\_D4, III in [Figure 1](#fig1){ref-type="fig"}; the amino acid sequence around the fusion is shown in [Figure 1---figure supplement 1Ab](#fig1s1){ref-type="fig"}). We then tested whether this chimeric ligand is sufficient for normal DLL1 function during development. We generated mice (*Dll1^D1N-E3_D4ki^*) expressing D1*N-E3*\_D4 instead of DLL1 using the \"mini-gene" knock-in strategy ([Figure 3A](#fig3){ref-type="fig"}) that disrupts endogenous *Dll1*, successfully employed previously to express either a *Dll4* or *Dll1* (control) mini-gene ([@bib41]; [@bib38]; [@bib43]). Heterozygous mice obtained from two independent targeting events carrying the *Dll1^D1N-E3_D4ki^* allele were viable and showed no apparent phenotype. Homozygous *Dll1^D1N-E3_D4ki^* mice were stillborn (n = 3 and 4, respectively), indicating that D1*N-E3*\_D4 cannot fully replace DLL1 during development although it is present on the cell surface of PSM cells ([Figure 3Cd-f](#fig3){ref-type="fig"}). At E15.5 homozygous *Dll1^D1N-E3_D4ki^* fetuses showed a stumpy tail (n = 5 and 6, respectively; arrow in [Figure 3Bb](#fig3){ref-type="fig"}) similar to *Dll1^Dll4ki^* mutants ([Figure 3Bd](#fig3){ref-type="fig"}); however, they lacked the edema observed in *Dll1^Dll4ki^* homozygotes (arrowhead in [Figure 3Bd](#fig3){ref-type="fig"}). D1*N-E3*\_D4 was also not able to restore normal *Uncx* expression ([Figure 3De](#fig3){ref-type="fig"}). Axial skeletons of homozygous *Dll1^D1N-E3_D4ki^* fetuses were severely disorganized (n = 10; [Figure 3Ef](#fig3){ref-type="fig"}), a phenotype consistent with abnormal *Uncx* expression and similar to *Dll1^Dll4ki/Dll4ki^* homozygote axial skeletons ([Figure 3Ed](#fig3){ref-type="fig"}), although the rib cage appeared less compressed. In contrast to *Dll1^Dll4ki^* heterozygotes ([Figure 3Ec](#fig3){ref-type="fig"}; [@bib38]), which often displayed axial skeleton defects (n = 14/16) such as hemivertebrae (arrow in [Figure 3Ec](#fig3){ref-type="fig"}) and fused ribs (arrowheads in [Figure 3Ec](#fig3){ref-type="fig"}) heterozygous *Dll1^D1N-E3_D4ki^* fetuses showed no defects of the axial skeleton (n = 0/14; [Figure 3Ee](#fig3){ref-type="fig"}) indicating that D1*N-E3*\_D4 lacks the dominant interfering activity of DLL4.

![D1*N-E3*\_D4 is not able to compensate for DLL1 function during somitogenesis.\
(**A**) \"Mini-gene" targeting strategy to express DLL1 or DLL4 variants from the *Dll1* locus (**a**) and alleles generated in this study (**d and e**). The *Dll1^Dll1ki^* (**b**) and *Dll1^Dll4ki^* (**c**) control alleles were described previously ([@bib38]; [@bib43]). *Dll1^D1N-E3_D4ki^* (**d**) encodes a fusion protein between the N-terminal part of DLL1 including EGF3 fused to EGF4 and the remaining C-terminal portion of DLL4 (III in [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1Ab](#fig1s1){ref-type="fig"}). *Dll1^D1contD4ki^* (**e**) encodes a DLL1 variant whose predicted amino acids of the MNNL and DSL domains that contact N1 are replaced by the corresponding amino acids of DLL4 (XI in [Figure 1](#fig1){ref-type="fig"}, [Figure 5C](#fig5){ref-type="fig"}, and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). All alleles have an identical structure and intron 9 and 10 sequences of *Dll1*. (**B**) External phenotypes of wild type (a; n = 19), homozygous *Dll1^D1N-E3_D4ki^* (b; n = 11), *Dll1^Dll1ki^* (c; n = 3) and *Dll1^Dll4ki^* (d; n = 3) control E15.5 fetuses. Arrow in (**b**) points to the short tail. Arrowhead in (**c**) points to edemas present in homozygous *Dll1^Dll4ki^* fetuses. (**C**) Indirect immunofluorescence staining of wild type (**a--c, j--l**), homozygous *Dll1^D1N-E3_D4ki^* (**d--f, m--o**), and homozygous *Dll1^Dll4ki^* (**g--i, p--r**) E9.5 PSMs using antibodies recognizing the extracellular domain of DLL4 (**a, d, g**) and DLL1 (**j, m, p**) and pan-Cadherin (panCad; **b, e, h, k, n, q**) showing expression of D1*N-E3*\_D4 and co-localization with the cell surface marker pan-Cadherin. Staining of D1*N-E3*\_D4 appears weaker than DLL4 most likely because much of the epitope recognized by the polyclonal anti-DLL4 antibody is missing in this chimeric protein. n ≥ 3; Scale bar = 5 µm. (**D**) WISH of E9.5 embryos showing that D1*N-E3*\_D4 does not restore normal *Uncx* expression (e; n = 10) resembling the *Dll1^Dll4ki^* phenotype (d; n = 7). (**E**) Skeletal preparations of wild type (a; n = 11), homozygous *Dll1^Dll1ki^* (b; n = 6), heterozygous (c; n = 14/16) and homozygous (d; n = 3) *Dll1^Dll4ki^*, and heterozygous (e; n = 14) and homozygous (f; n = 10) *Dll1^D1N-E3_D4ki^* E15.5 fetuses. Arrow and arrowheads in (**c**) point to axial skeleton defects that were not detected in *Dll1^D1N-E3_D4ki^* heterozygotes (**e**). (**F**) Cross-sections of hind limbs of wild type (**a**), homozygous *Dll1^Dll1ki^* (**b**), homozygous *Dll1^Dll4ki^* (**c**), and homozygous (d-f; n = 3) *Dll1^D1N-E3_D4ki^* E18.5 fetuses stained for expression of Myosin Heavy Chain (MHC) indicating that D1*N-E3*\_D4 rescues the skeletal muscle phenotype in contrast to DLL4. Arrows in (**c**) point to skeletal muscle remnants.](elife-40045-fig3){#fig3}

Deletion of DLL1 during myogenesis leads to premature differentiation of myogenic progenitor cells resulting in severe skeletal muscle hypotrophy at fetal stages ([@bib41]). This phenotype cannot be suppressed by DLL4 expression ([Figure 3Fc](#fig3){ref-type="fig"}; [@bib38]). In contrast, skeletal muscles of *Dll1^D1N-E3_D4ki/D1N-E3_D4ki^* homozygotes ([Figure 3Fd-f](#fig3){ref-type="fig"}; n = 3) were virtually indistinguishable from *Dll1^Dll1ki/Dll1ki^* ([Figure 3Fb](#fig3){ref-type="fig"}) and wild type fetuses ([Figure 3Fa](#fig3){ref-type="fig"}). These in vivo analyses indicate that, unlike the D1*ECD*\_D4*ICD* chimera, D1*N-E3*\_D4 is not a fully functional DLL1 ligand during somite patterning. However, D1*N-E3*\_D4 remains functional during myogenesis and restricts muscle progenitor differentiation despite the presence of the DLL4 ICD, consistent with the conclusion that in vivo the functional difference between DLL1 and DLL4 is encoded in the ECDs.

DLL1 and DLL4 exhibit differential receptor selectivity in vitro {#s2-3}
----------------------------------------------------------------

In cell-based trans-activation assays using HeLa cells stably expressing murine N1 (HeLaN1) co-cultured with CHO cells expressing mouse DLL1 (mDLL1) or DLL4 from the same locus both ligands activated a transiently expressed Notch reporter similarly ([@bib38]). However, a purified fragment of the extracellular domain of human DLL4 (N-terminus up to and including EGF5: hD4*N-E5*) bound to hN1 with an approximately ten-fold higher affinity than the corresponding hDLL1 fragment ([@bib1]). Like hD4*N-E5*, mD4*N-E5* has a higher affinity for hN1 (K~D~ = 0.43 ± 0.046 µM; [Figure 1---figure supplement 2Aa](#fig1s2){ref-type="fig"}) than the corresponding mDLL1 fragment (K~D~ = 1.56 ± 0.207 µM; [Figure 1---figure supplement 2Ab](#fig1s2){ref-type="fig"}), as judged by biolayer interferometry measurements. To find a potential explanation for the discrepancy between binding affinities and Notch activation in HeLaN1 cells we analyzed these cells for expression of other Notch receptors and found that in addition to exogenous mouse *Notch1* HeLaN1 cells express endogenous *NOTCH2* and *NOTCH3* ([Figure 4A](#fig4){ref-type="fig"}), which might have masked underlying differences in the intrinsic N1 response to the DLL1 and DLL4 ligands.

![DLL1 and DLL4 differentially activate NOTCH1 and NOTCH2 in cell-based co-culture assays.\
(**A**) RT-PCR analysis using RNA of HeLaN1 cells shows the expression of endogenous human *NOTCH2* and *NOTCH3* in addition to the exogenous murine *Notch1.* (**B**) ES cell-based trans-activation assays demonstrate that E14TG2a ES cells express negligible amounts of endogenous Notch receptors and ligands. Co-cultivation of ES cells with stable expression of either DLL1 (III) or DLL4 (IV) from the *Hprt*-locus with ES-cells carrying only the RBP-Luc reporter in the *Hprt*-locus (E14rep) showed luciferase activity at levels indistinguishable from lysates of only E14 cells (I) and co-cultures of wild type E14 and reporter carrying ES cells (II). Similarly, co-culture of ES cells carrying N1 and the RBP-Luc reporter (N1rep) with E14 cells (V) did not show reporter activation significantly above background levels, whereas co-culture of DLL1 expressing cells with N1rep ES cells showed a 6--10-fold increase in luciferase activity (VI). n ≥ 3 co-cultures with 2--4 replicate measurements per n ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Mean ± SD, ns = p ≥ 0.05, \*\*\*\*=p \< 0.0001, one-way ANOVA followed by Tukey's multiple comparison test. (**C**) Protein expression analysis indicating similar expression levels of DLL1 and DLL4 in the ES cell clones used. Each DLL4 value represents a technical replicate, which was referenced to its paired DLL1 value, which was arbitrarily set to one for each measurement. The non-normalized values (DLL/β-Tub ratios) are depicted in a graph in [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} ([Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). (**D**) Cell-surface biotinylation demonstrating that a slightly higher fraction of DLL4 is present at the cell surface compared to DLL1 (n ≥ 6; [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}). (**E**) DLL4 activates N1 about 10-fold more strongly than DLL1 in co-culture assays. Left graph shows non-normalized N1 activation. Lines connect values measured in the same assay. Right graph shows values normalized to DLL1 activation, and corrected for protein expression and cell surface presentation. (**F**) DLL4 activates N2 about half as strongly as does DLL1. Left graph shows non-normalized N2 activation. Lines connect values measured in the same assay. Right graph shows values normalized to DLL1 activation, and corrected for protein expression and cell surface presentation. Each dot represents a technical replicate. Raw data are shown in [Figure 4---source data 4](#fig4sdata4){ref-type="supplementary-material"} and [Figure 4---source data 5](#fig4sdata5){ref-type="supplementary-material"}. Co-cultures (n = 39) with two replicate measurements per n. Mean ± SD, ns = p ≥ 0.05, \*\*\*\*=p \< 0.0001, Student's paired t-test.\
10.7554/eLife.40045.013Figure 4---source data 1.Raw data used to generate the graph in [Figure 4B](#fig4){ref-type="fig"}.Relative luciferase activity (units) of different assays are means of ≥2 technical replicates (measurements of the same cell lysate) of each (co-)culture.\
10.7554/eLife.40045.014Figure 4---source data 2.Data used to generate the graphs in [Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}.DLL1 and DLL4 protein expression level in ES cells determined by quantitative analysis of Western blots (DLL1 or DLL4 expression intensity/𝛽-Tubulin intensity (DLL/𝛽-Tub)). Expression of DLL4 clone \#1 was normalized to expression of DLL1 clone \#1 analyzed in the same assay. The value obtained in Assay \#7 (red) represents an outlier (determined by GraphPad Prism7) and was not included in the calculation of the average.\
10.7554/eLife.40045.015Figure 4---source data 3.Raw data used to generate the graph in [Figure 4D](#fig4){ref-type="fig"}.Relative cell surface levels of DLL1 (ES clone \#1) and DLL4 (ES cell clone \#1) proteins determined by cell surface biotinylation and quantitative analysis of Western blots after immunoprecipitation.\
10.7554/eLife.40045.016Figure 4---source data 4.Numerical values used to generate the graphs in [Figure 4E](#fig4){ref-type="fig"}.Relative luciferase activity (units) for each assay was calculated by subtraction of E14 background values. Normalized activation (fold change) was obtained by normalization to DLL1 activity and correction for protein and cell surface levels based on the values for relative protein expression ([Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}) and cell surface presentation ([Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}). Normalized activation = normalized activation x \[prot level DLL1/prot level DLL4\] x \[rel surface level DLL1/rel surface level DLL4\].\
10.7554/eLife.40045.017Figure 4---source data 5.Numerical values used to generate the graphs in [Figure 4F](#fig4){ref-type="fig"}.Luciferase activity (units) for each assay was calculated by subtraction of the E14 background values. Normalized activation (fold change) was obtained by normalization to DLL1 activity and correction for protein and cell surface levels based on the values for relative protein expression ([Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}) and cell surface presentation ([Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}). Normalized activation = normalized activation x \[prot level DLL1/prot level DLL4\] x \[rel surface level DLL1/rel surface level DLL4\].](elife-40045-fig4){#fig4}

To detect potential differences in ligand activity towards N1 or N2, the two Notch receptors present during somitogenesis, and to reduce variability due to transient reporter expression we stably integrated a Notch luciferase reporter in the *Hprt* locus (E14rep) of mouse E14TG2a ES (E14) cells, and generated stable cell lines expressing either *Notch1* (N1rep) or *Notch2* (N2rep) in these cells ([@bib43]). When co-cultured with E14 cells or DLL1 or DLL4 expressing cells, E14rep cells show luciferase activity similar to wild type E14 levels (compare I to II, III, and IV in [Figure 4B](#fig4){ref-type="fig"}; numerical values in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), indicating that negligible amounts of functional endogenous NOTCH receptors are present in E14 cells. Likewise, N1rep cells show essentially no activation above background when co-cultured with wild type E14 ES cells (compare V to I in [Figure 4B](#fig4){ref-type="fig"}; numerical values in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), indicating insignificant amounts of functional endogenous Notch ligands in these cells. ES cells expressing exogenous DLL1 activate the luciferase reporter approximately ten-fold above the basal signal in E14 ES cells when co-cultured with N1rep cells (compare VI to V in [Figure 4B](#fig4){ref-type="fig"}; numerical values in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}) indicating that our co-culture system reliably measures specific Notch signaling activity.

To create ligand presenting cells for a comparison between mDLL1 and mDLL4, we generated ES cells expressing either mDLL1 or mDLL4 from single copy integrations into the *Hprt* locus. Co-cultures (n = 39) of cells expressing DLL1 or DLL4 with N1rep ES cells consistently revealed higher activation of N1 by DLL4 than by DLL1 (mean 12.454 ± 3.961 SD fold of non-normalized luciferase activity, 9.42 ± 2.997 SD fold, when normalized to DLL1 activation and corrected for protein expression and cell surface levels ([Figure 4C--E](#fig4){ref-type="fig"}; numerical values [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}, [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}, [Figure 4---source data 4](#fig4sdata4){ref-type="supplementary-material"}). In contrast, DLL4 activated N2 significantly less efficiently than did DLL1 (n = 39; mean 0.468 ± 0.161 SD fold of non-normalized luciferase activity, 0.35 ± 0.12 SD fold, when normalized to DLL1 activation and corrected for protein expression and cell surface levels ([Figure 4F](#fig4){ref-type="fig"}; numerical values in [Figure 4---source data 5](#fig4sdata5){ref-type="supplementary-material"}). To confirm that the observed differences between DLL1 and DLL4 in activating N1 and N2 were not a secondary consequence of clonal selection (however unlikely), we also analyzed additional DLL1 (n = 3) and DLL4 (n = 9) expressing ES cell clones for protein expression and N1 or N2 activation. Despite some variability of protein expression ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"} and [Figure 4---figure supplement 1---source data 1](#fig4s1sdata1){ref-type="supplementary-material"}) and Notch activation levels between individual clones and co-cultures, all DLL4 clones consistently activated N1 significantly better than all DLL1 clones, and all DLL4 clones stimulated N2 significantly less efficiently than DLL1 ([Figure 4---figure supplement 1C,D](#fig4s1){ref-type="fig"}; numerical values in [Figure 4---figure supplement 1---Source Data 2](#fig4s1sdata2){ref-type="supplementary-material"}), indicating that both ligands differ significantly in their ability to activate different Notch receptors in our cell-based assay. Consistent with the differences in N2 stimulation by mDLL1- and mDLL4-expressing cells, the highly homologous human hD1*N-E5* exhibits a higher affinity (K~D~ = 0.36 ± 0.11 µM; [Figure 1---figure supplement 2Ba](#fig1s2){ref-type="fig"}) for human NOTCH2 than D4*N-E5* (K~D~ = 1.28 ± 0.2 µM; [Figure 1---figure supplement 2Bb](#fig1s2){ref-type="fig"}).

The region encompassing the MNNL up to and including EGF3 encodes the differential receptor selectivity of DLL1 and DLL4 {#s2-4}
------------------------------------------------------------------------------------------------------------------------

In an attempt to identify the domains of DLL1 and DLL4 that contribute to differences in activating N1 and N2, we carried out a series of domain swaps to generate a set of chimeric ligands (II-V, VII-X in [Figure 1](#fig1){ref-type="fig"}) for stimulation of N1 and N2-expressing cells in our co-culture assay. Like wild-type ligands, chimeric ligands were expressed from single copy transgene integrations in the *Hprt* locus of murine ES cells. All chimeric proteins were expressed and present on the cell surface ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), but expression levels varied among the chimeras ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) despite integration into the *Hprt* locus by homologous recombination. We thus analyzed receptor selectivity of the chimeras in stimulating N1 and N2 responses using the co-culture assay by determining the N1/N2 response ratio. Stimulation with DLL1 gives a N1/N2 response ratio of approximately 1, DLL4 of \~20 ([Figure 5A](#fig5){ref-type="fig"}; numerical values used for calculations in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}, [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}; graphical representations of the relative luciferase activities of the ligands are shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Strikingly, chimeras which retain the full ectodomain or the MNNL-EGF3 region of DLL4 have a N1/N2 stimulation ratio of approximately 20 similar to DLL4, whereas chimeras that retain the ectodomain, or MNNL-EGF3 region of DLL1 have a stimulation ratio of between one and two, resembling DLL1 ([Figure 5A](#fig5){ref-type="fig"}). These results indicate that the differences in activation potential of DLL4 and DLL1 toward N1 and N2 are encoded in the N-terminal part of the protein, encompassed by MNNL-EGF3. When chimeras include the MNNL-EGF2 or MNNL-DSL region of one ligand and the remainder of the other, the N1/N2 stimulation ratios of the chimeric pairs are equivalent ([Figure 5A](#fig5){ref-type="fig"}), indicating that the third EGF-like repeat makes an important contribution to receptor selectivity.

![Contributions of the MNNL-EGF3 portion and contact amino acids to ligand selectivity towards N1 and N2.\
(**A**) N1/N2 activation ratios by DLL1 and DLL4 chimeric proteins show that receptor selectivity of DLL1 and DLL4 is encoded by the extracellular domain and that EGF3 contributes to N1/N2 selectivity. DLL4, D4*ECD*\_D1*ICD*, and D4*N-E3*\_D1 show N1/N2 induction ratios of \~20. DLL1, D1*ECD*\_D4*ICD*, and D1*N-E3*\_D4 exhibit induction ratios of 1--3. Chimeric pairs with domain exchanges between EGF2 and EGF3 or between DSL domain and EGF1 show equivalent stimulation ratios. Each dot represents the mean of N1 (relative luciferase units; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"})/N2 (relative luciferase units; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}) of n ≥ 3 measurements per clone of a given ligand construct. Bars represent the Mean ± SD of n ≥ 3 clones per construct ([Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}). (**B**) Structure-based superposition of DLL1 and DLL4 (PDB ID codes 4XBM and 4XLW, respectively; ([@bib21]; [@bib28]). Top panel: NOTCH1 is rendered as a molecular surface (wheat), and DLL4 is rendered in ribbon representation (cyan). N1 contact residues on DLL4 were rendered as sticks, and were used to predict N1 contact amino acids of the MNNL and DSL domains of DLL1 (red). Domains are labeled above and below the structures, respectively, and individual domains are identified by different degrees of color shading/intensity. (**C**) Parts of the MNNL and DSL sequences showing the contact amino acids (boxed), the divergent amino acids of DLL1 (red) and DLL4 (blue), and the sequence of ligands with amino acid exchanges (complete sequences of the changed MNNL and DSL domains are shown in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). The N-glycosylation site at residue N109 of DLL4 is indicated in green. (**D**) N1/N2 activation ratios of ligands with exchanged N1 contact amino acids. D1contD4 does not show changes in receptor selectivity compared to DLL1. Replacing the contact residues of DLL4 with those of DLL1 only reduces N1/N2 activation ratio to \~13. Elimination of the N-glycosylation site of DLL4 with the N109G mutation (the corresponding amino acid of DLL1) does not change DLL4 receptor selectivity. Each dot represents the mean of N1 (relative luciferase units; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"})/N2 (relative luciferase units; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}) of n ≥ 3 measurements per clone of a given ligand construct. Bars represent the Mean ± SD of n ≥ 3 clones per construct ([Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}).\
10.7554/eLife.40045.020Figure 5---source data 1.Raw data (RLUs) of luciferase activity in co-cultures with N1rep cells used to generate the graph in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}.Values represent relative luciferase activity (units) after subtraction of E14 background RLUs.\
10.7554/eLife.40045.021Figure 5---source data 2.Raw data (RLUs) of luciferase activity in co-cultures with N1rep cells used to generate the graph in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}.Values represent relative luciferase activity (units) after subtraction of E14 background RLUs.\
10.7554/eLife.40045.022Figure 5---source data 3.N1/N2 activation ratios.Values represent N1/N2 activation ratio. Values were used for generation of graphs in [Figure 5A and D](#fig5){ref-type="fig"}. Red values were identified as outliers (determined by ROUT analysis by GraphPad Prism7) and excluded from calculations.](elife-40045-fig5){#fig5}

Regions outside of the MNNL-DSL contact interface contribute to the functional difference of DLL1 and DLL4 in vitro and in vivo {#s2-5}
-------------------------------------------------------------------------------------------------------------------------------

To analyze to what extent the amino acids that contact N1 in the binding interfaces of the MNNL and DSL domains might contribute to the different activity of DLL1 and DLL4 toward N1 and N2 we reciprocally exchanged these amino acids (XI-XII in [Figure 1](#fig1){ref-type="fig"}; [Figure 5C](#fig5){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) based on alignments of the DLL4 ([@bib28]) and DLL1 ([@bib21]) structures ([Figure 5B](#fig5){ref-type="fig"}). Western blot analyses of cell lysates and cell surface biotinylation and immunoprecipitation showed that all variants were present on the cell surface ([Supplementary File 1](#supp1){ref-type="supplementary-material"}). The N1/N2 response ratios show that swapping the contact residues of DLL4 onto DLL1 do not substantially affect the activation ratio when compared to DLL1 itself, indicating that the differences between DLL1 and DLL4 in N1/N2 selectivity cannot simply be accounted for by interfacial residues in the MNNL-DSL region ([Figure 5D](#fig5){ref-type="fig"}; numerical values used for calculations are in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}, [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}). Similarly, replacement of the DLL4 contact residues by the analogous residues of DLL1 slightly reduces the mean N1/N2 activation ratio (to \~13), but does not collapse the ratio to 1 ([Figure 5D](#fig5){ref-type="fig"}), again strongly suggesting that residues outside of the MNNL-DSL contact interface contribute to the relative N1 selectivity of DLL4. These results are consistent with 1) the domain swap data, which argue that discrimination between DLL1 and DLL4 depends on the EGF repeats as well as on the MNNL-DSL region, and 2) the prior observation that variants of DLL4 selected for high N1 affinity accumulate mutations in the protein core, but not in the binding interface ([@bib28]). Swapping the contact residues of DLL1 onto DLL4 did not reduce the binding affinity of DLL4 for N1 (D4contD1 K~D~ = 0.327 ± 0.036 µM; [Figure 1---figure supplement 2Ac](#fig1s2){ref-type="fig"}), fully consistent with the interpretation that the protein core of DLL4 contributes to N1 binding affinity, likely by influencing the fraction of molecules in a binding-active conformation. Although swapping the contact residues of DLL4 onto DLL1 increased binding affinity for N1 (D1contD4 K~D~ = 0.326 ± 0.044 µM; [Figure 1---figure supplement 2Ad](#fig1s2){ref-type="fig"}), the substitution did not substantially change the N1/N2 activation ratio, indicating that binding affinity for N1 is not the only influence on the selectivity of the two ligands for N1 or N2.

The DLL4 MNNL domain contains three N-glycosylation sites, one of which (N109) is conserved from amphibian to mammalian DLL4 ligands but absent in DLL1. This residue resides adjacent to the contact amino acid F110 ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). We confirmed that DLL4 can actually be N-glycosylated at this site ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}) and tested whether N109-glycosylation contributes to DLL4 activity and selectivity by mutating N109 to G (XIII in [Figure 1](#fig1){ref-type="fig"}), which is the amino acid present in DLL1 in the equivalent position (G112). D4^N109G^ had no effect on the relative activation potential of DLL4 for N1 versus N2 ([Figure 5D](#fig5){ref-type="fig"}), and its affinity for N1 was not altered (K~D~ = 0.341 ± 0.015 µM; [Figure 1---figure supplement 2Ae](#fig1s2){ref-type="fig"}), indicating that N-glycosylation at this site does not significantly modulate N1 binding or contribute to the relative selectivity of DLL4 towards N1 and N2.

To test whether the contact amino acids of DLL1 and DLL4 contribute to their functional divergence in vivo we generated a mouse line expressing D1contD4 (XI in [Figure 1](#fig1){ref-type="fig"}) instead of wild type DLL1 using our \"mini-gene\" knock-in strategy ([Figure 3A](#fig3){ref-type="fig"}). Heterozygous mice carrying this allele (*Dll1^D1contD4ki^*) are indistinguishable from wild type. Homozygous mutants obtained from heterozygous matings at the expected Mendelian ratio (6/27) were viable and fertile, and indistinguishable from wild type and *Dll1^Dll1ki/Dll1ki^* controls ([Figure 6A](#fig6){ref-type="fig"}). *Uncx* was expressed in regular pattern in the caudal halves of the somites of homozygous embryos ([Figure 6Cd,d'](#fig6){ref-type="fig"}), consistent with only subtle abnormalities of individual vertebral bodies in the lower thoracic region of *Dll1^D1contD4ki/D1contD4ki^* fetuses ([Figure 6D](#fig6){ref-type="fig"}; n = 3/4) indicating that the contact amino acids and different binding affinities are not a major discriminating feature of the two ligands in vivo.

![DLL1 carrying the DLL4 contact amino acids in the MNNL and DSL domains is a functional DLL1 ligand in vivo.\
(**A**) E15.5 *Dll1^D1contD4ki/D1contD4ki^* (c; n = 12) fetuses are indistinguishable from wild type (a; n = 19) and *Dll1^Dll1ki/Dll1ki^* (b; n = 3) controls. (**B**) D1contD4 co-localizes with pan-Cadherin (panCad) at the cell surface of *Dll1^D1contD4ki/D1contD4ki^* PSM cells (e-h; n ≥ 3); Scale bars: a, e = 500 µm; b-d, f-h = 5 µm. (**C**) Whole mount in situ hybridization showing that D1contD4 induces normal *Uncx* expression during somitogenesis (d,d'; n ≥ 5). (**D**) Skeletal preparations of *Dll1^D1contD4ki/D1contD4ki^* E15.5 fetuses showing minor defects of single vertebrae in the lower thoracic region (c,c'; n = 3/4).](elife-40045-fig6){#fig6}

Discussion {#s3}
==========

DLL1 and DLL4 have context-dependent redundant and divergent functions, but the bases for these differences are unclear. Here, using systematic domain exchanges and mutation of contact amino acids in the MNNL and DSL domains of DLL1 and DLL4, cell-based and biochemical assays, and transgenic mice we show that (1) DLL1 and DLL4 differ significantly in their potential to activate N1 and N2 and this difference is encoded in the ligand ectodomains, (2) regions outside the known contact interface contribute to context-dependent ligand function, and (3) the contact amino acids are not the sole or primary determinant of this discrimination between the two receptors.

Analysis of our transgenic mice expressing D1*ECD*\_D4*ICD* or D4*ECD*\_D1*ICD* indicate a critical role of the ECD for the function of DLL1 during somite patterning in vivo. This resembles intrinsic functional differences that reside in the extracellular domains of mN1 and mN2 during kidney development ([@bib24]), whereas the N1 and N2 ICDs appear to be functionally equivalent in various developmental contexts ([@bib25]). Functional equivalence of DLL1's and DLL4's ICDs in vivo is further supported by the rescue of the skeletal muscle phenotype in our D1*N-E3*\_D4 knock-in mice, which harbor the DLL4 ICD. In this developmental context even domains C-terminal to EGF3 of DLL1 appear to be interchangeable. Analyses of the ECD/ICD domain swaps in the cell-based assay also suggest that the discriminatory potential of the ligands tracks with the ECD, and not with the ICD, even though the ICD appears to affect the strength and/or dynamics of the signal in co-culture assays where ligand and receptor expression is enforced in vitro ([@bib34]). Additional sources of complexity in vivo, like the stronger cis-inhibitory potential of the DLL4 ECD on Notch signaling ([@bib38]), or cyclic modulation of Notch by LFNG in the paraxial mesoderm, or different interactions with lipids ([@bib47]) might account for the resistance to loss of function phenotypes from ligand ICD swaps in vivo.

EGF-like repeats 11 and 12 of mouse N1 and N2 are highly similar (56/83 residues identical, 14 similar amino acids), and 13 of the 17 amino acid residues at the DLL4-binding interface are identical. Moreover, the x-ray structures of the EGF11-13 fragments of human N1 and N2 adopt a very similar arrangement ([@bib47]). Nevertheless, DLL1 and DLL4 exhibit a \"discrimination potential\" of \~20 fold in terms of receptor response in culture assays, suggesting that either the few different contact amino acids in EGF 11 and 12 of N1 and N2 have a significant impact or interactions of DLL1 and DLL4 with N1 and N2 are not limited to the MNNL and DSL interfaces with receptor EGF repeats 11 and 12. Domain swaps carried out here show that the region responsible for this receptor discrimination maps to the MNNL-EGF3 region ([Figure 5](#fig5){ref-type="fig"}). These findings are consistent with previous work uncovering the requirement of EGF repeats 1--3 of the DLL ligands for NOTCH1 activation, the importance of this region in the binding of Serrate family ligands to Notch receptors and in Serrate/Jagged-induced signaling, and the importance of EGF repeats 8--10 of NOTCH1 for signal activation by DLL ligands ([@bib44]; [@bib13]; [@bib50]; [@bib1]; [@bib43]; [@bib29]; [@bib26]). Together, this body of work suggests that interactions of the N-terminal EGF repeats of the DLL ligands with EGF repeats 8--10 of Notch also contribute to recognition and impart discriminatory potential. The D1*N-E3*\_D4 knock-in mice also point a functional role for domains outside the known binding interface, since this chimeric ligand does not substitute fully for DLL1 in vivo during somite patterning despite harboring the MNNL and DSL domains and EGF1-3 of DLL1, supporting context-dependent contributions of additional C-terminal EGF repeats observed previously in mice ([@bib43]).

Remarkably, the exchange of the contact amino acids in DLL1 with those of DLL4 in the D1contD4 protein does not alter receptor selectivity in cultured cells even though these changes increase N1 binding affinity. This result suggests that receptor selectivity of DLL1 and DLL4 is not determined exclusively by the differences in binding strength. The D1contD4 chimera even substitutes almost completely for DLL1 function in mice during somite patterning, which is highly sensitive to altered Notch signaling ([@bib42]) and therefore a suitable in vivo read out to detect even minor differences of Notch ligand function. Together, our results also favor the conclusion that the contact amino acids in the MNNL and DSL domains do not make the dominant contributions to the functional divergence of DLL1 and DLL4 in vivo, suggesting instead that differences in the domain cores, and/or contacts outside of the known DLL4-NOTCH1 interface, are the factors that most contribute to this functional divergence.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                 Designation                   Source or reference        Identifiers                                                              Additional\
  (species) or resource                                                                                                                                           information
  ----------------------------- ----------------------------- -------------------------- ------------------------------------------------------------------------ ---------------------------------
  Gene\                         DLL1                          MGI:104659;\                                                                                        
  (*Mus musculus*)                                            NCBI Gene:\                                                                                         
                                                              13388                                                                                               

  Gene\                         DLL4                          MGI:1859388;\                                                                                       
  (*Mus musculus*)                                            NCBI Gene:\                                                                                         
                                                              54485                                                                                               

  Strain,\                      CD1                           Charles River\                                                                                      
  strain background\                                          Laboratories                                                                                        
  (Mus musculus)                                                                                                                                                  

  Strain, strain\               129Sv/CD1 hybrids             own colony                                                                                          
  background\                                                                                                                                                     
  (Mus musculus)                                                                                                                                                  

  Genetic reagent\              *Dll1^lacZ^*                  PMID: 9109488;\            RRID:[MGI:5780046](https://scicrunch.org/resolver/MGI:5780046)           
  (*Mus musculus*)                                            DOI: 10.1038/\                                                                                      
                                                              386717a0                                                                                            

  Genetic reagent\              *Dll1^loxP^*                  PMID: 15146182;\           RRID:[MGI:5431505](https://scicrunch.org/resolver/MGI:5431505)           
  (*Mus musculus*)\                                           DOI: 10.1038/\                                                                                      
                                                              ni1075                                                                                              

  Genetic reagent\              T(s):Cre                      PMID: 18708576;\           MGI:3811072                                                              
  (*Mus musculus*)                                            PMCID: PMC2518812;\                                                                                 
                                                              DOI: 10.1101/gad.\                                                                                  
                                                              480408                                                                                              

  Genetic reagent\              ZP3:Cre                       PMID: 10686600             MGI:2176187                                                              
  (*Mus musculus*)                                                                                                                                                

  Genetic reagent\              *Dll1^Dll1ki^*                PMID: 26801181;\           MGI:5790945                                                              
  (*Mus musculus*)                                            PMCID: PMC4788113;\                                                                                 
                                                              DOI: 10.1534/genetics.\                                                                             
                                                              115.184515                                                                                          

  Genetic reagent\              *Dll1^Dll4ki^*                PMID: 26114479;\           MGI:5779556                                                              
  (*Mus musculus*)                                            PMCID: PMC4482573;\                                                                                 
                                                              DOI: 10.1371/journal.\                                                                              
                                                              pgen.1005328                                                                                        

  Genetic reagent\              *Dll1^D1N-E3_D4ki^*           this paper                                                                                          mini gene\
  (*Mus musculus*)                                                                                                                                                insertion in the\
                                                                                                                                                                  *Dll1* locus

  Genetic reagent\              *Dll1^D1contD4ki^*            this paper                                                                                          mini gene insertion\
  (*Mus musculus*)                                                                                                                                                in the *Dll1* locus

  Genetic reagent\              *Hprt^Dll1ECD_Dll4ICD^*       this paper                                                                                          inducible insertion\
  (*Mus musculus*)                                                                                                                                                into *Hprt* locus

  Genetic reagent\              *Hprt^Dll4ECD_Dll1ICD^*       this paper                                                                                          inducible insertion\
  (*Mus musculus*)                                                                                                                                                into *Hprt* locus

  Cell line\                    E14TG2a                       PMID: 26114479;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4482573;\                                                                                 
                                                              DOI: 10.1371/journal.\                                                                              
                                                              pgen.1005328                                                                                        

  Cell line\                    129Sv/cast                    PMID: 26114479;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4482573;\                                                                                 
                                                              DOI: 10.1371/journal.\                                                                              
                                                              pgen.1005328                                                                                        

  Cell line (*Homo sapiens*)    HeLaN1                        PMID: 9653148;\                                                                                     
                                                              DOI: 10.1073/pnas.\                                                                                 
                                                              95.14.8108                                                                                          

  Cell line\                    pMP8.CAG-DLL1                 PMID: 26801181;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4788113;\                                                                                 
                                                              DOI: 10.1534/genetics.\                                                                             
                                                              115.184515                                                                                          

  Cell line\                    E14rep                        PMID: 26801181;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4788113;\                                                                                 
                                                              DOI: 10.1534/genetics.\                                                                             
                                                              115.184515                                                                                          

  Cell line\                    N1rep                         PMID: 26801181;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4788113;\                                                                                 
                                                              DOI: 10.1534/genetics.\                                                                             
                                                              115.184515                                                                                          

  Cell line\                    N2rep                         PMID: 26801181;\                                                                                    
  (*Mus musculus*)                                            PMCID: PMC4788113;\                                                                                 
                                                              DOI: 10.1534/genetics.\                                                                             
                                                              115.184515                                                                                          

  Bacterial strain\             SW106                         PMID:15731329                                                                                       
  (*E. coli*)                                                                                                                                                     

  Transfected\                  pMP8.CAG-DLL4                 this paper                                                                                          progenitor: pMP8.CAG
  construct\                                                                                                                                                      
  (*Mus musculus*)                                                                                                                                                

  Transfected\                  pMP8.CAG-D1ECD\               this paper                                                                                          progenitor: pMP8.CAG
  construct\                    \_D4ICD                                                                                                                           
  (*Mus musculus*)                                                                                                                                                

  Transfected\                  pMP8.CAG-D1N-\                this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    E3_D4                                                                                                                             

  Transfected\                  pMP8.CAG-D1N-\                this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    E2_D4                                                                                                                             

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    D1N-D_D4                                                                                                                          

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    D4ECD_D1ICD                                                                                                                       

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    D4N-E3_D1                                                                                                                         

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    D4N-E2_D1                                                                                                                         

  \                             pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  Transfected\                  D4N-D_D1                                                                                                                          
  construct (*Mus musculus*)                                                                                                                                      

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)    D1contD4                                                                                                                          

  Transfected\                  pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  construct (*Mus musculus*)\   D4contD1                                                                                                                          

  Transfected construct\        pMP8.CAG-\                    this paper                                                                                          progenitor: pMP8.CAG
  (*Mus musculus*)              D4N109G                                                                                                                           

  Transfected\                  pMP8.CAG-Stop\                this paper                                                                                          progenitor: pMP8.CAG
  construct\                    -D1ECD_D4ICD                                                                                                                      
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pMP8.CAG-Stop-\               this paper                                                                                          progenitor: pMP8.CAG
  (*Mus musculus*)              D4ECD_D1ICD                                                                                                                       

  Transfected construct\        D1N-E3_D4-targeting           this paper                                                                                          based on Dll1Dll1ki targeting
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        D1contD4-targeting            this paper                                                                                          based on Dll1Dll1ki targeting
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-Avi-His                 this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D1N-E5-Avi-His          this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D4N-E5-Avi-His          this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D1N-E3_D4-E5-Avi-His    this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D4N-E3_D1-E5-Avi-His    this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D1contD4-E5-Avi-His     this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)\                                                                                                                                               

  Transfected construct\        pLexM-D4contD1-E5-Avi-His     this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Transfected construct\        pLexM-D4N109G-E5-Avi-His      this paper                                                                                          progenitor: pLexM
  (*Mus musculus*)                                                                                                                                                

  Antibody                      Rat anti-DLL1                 PMID: 17664336;\           (1F9, rat monoclonal)                                                    1:50 (IF)
                                                              PMCID: PMC2064846;\                                                                                 
                                                              DOI: 10.1083/jcb.\                                                                                  
                                                              200702009                                                                                           

  Antibody                      Goat anti-DLL4                R and D Systems            Cat. \#AF1389\                                                           1:50 (IF)
                                                                                         RRID:[AB_354770](https://scicrunch.org/resolver/AB_354770)               

  Antibody                      Mouse anti-\                  Sigma-Aldrich              Cat.\                                                                    1:250 (IF)
                                panCadherin                                              \#C1821 RRID:[AB_476826](https://scicrunch.org/resolver/AB_476826)       

  Antibody                      Donkey anti-\                 Invitrogen                 Cat.\                                                                    1:100 (IF)
                                mouse Alexa 555                                          \#A-31570 RRID:[AB_2536180](https://scicrunch.org/resolver/AB_2536180)   

  Antibody                      Donkey anti-goat\             Invitrogen                 Cat.\                                                                    1:100 (IF)
                                Alexa 488                                                \#A-11055\                                                               
                                                                                         RRID:[AB_2534102](https://scicrunch.org/resolver/AB_2534102)             

  Antibody                      Donkey anti-rat\              Invitrogen                 Cat.\                                                                    1:100 (IF)
                                Alexa 488                                                \#A-21208 RRID:[AB_2535794](https://scicrunch.org/resolver/AB_2535794)   

  Antibody                      Anti-FLAG-\                   Sigma-Aldrich              (M2 mouse,\                                                              1:10 000 (WB)
                                Peroxidase (HRP)                                         monoclonal purified)\                                                    
                                                                                         Cat.\                                                                    
                                                                                         \#A8592 RRID:[AB_439702](https://scicrunch.org/resolver/AB_439702)       

  Antibody                      Mouse anti-β-Tubulin          Sigma-Aldrich              Cat.\                                                                    1:500 000; 1:1 000 000 (WB)
                                                                                         \#T7816 RRID:[AB_261770](https://scicrunch.org/resolver/AB_261770)       

  Antibody                      Anti-mouse HRP                Amersham                   Cat.\                                                                    1:10 000 (WB)
                                                                                         \#NA931 RRID:[AB_772210](https://scicrunch.org/resolver/AB_772210)       

  Antibody                      MHC (Myosin\                  Sigma-Aldrich              Cat.\                                                                    1:250 (IHC)
                                Heavy Chain)                                             \#M4276 RRID:[AB_477190](https://scicrunch.org/resolver/AB_477190)       

  Antibody                      Anti-DIG AP\                  Roche                      Cat.\                                                                    1: 5 000 (ISH)
                                fab fragment                                             \#1093274                                                                

  Antibody                      Anti-mouse\                   Vector Laboratories        Cat.\                                                                    1:200 (IHC)
                                biotinylated\                                            \#BA-9200 RRID:[AB_2336171](https://scicrunch.org/resolver/AB_2336171)   
                                (BA9200/goat)                                                                                                                     

  Commercial assay\             Luciferase Cell Culture\      Promega                    Cat. \#E1531                                                             
  or kit                        Lysis 5X Reagent                                                                                                                  

  Commercial assay\             Luciferase Assay\             Promega                    Cat. \#E1483                                                             
  or kit\                       Reagent                                                                                                                           

  Commercial assay\             SuperScript IV\               Invitrogen                 Cat. \#18090050                                                          
  or kit                        Reverse Transcriptase                                                                                                             

  Commercial assay\             Expand\                       Roche                      Cat. \#04743733001                                                       
  or kit                        High-Fidelity\                                                                                                                    
                                PCR system                                                                                                                        

  Commercial assay\             Tri-Reagent                   Sigma-Aldrich              Cat. \#T9424                                                             
  or kit                                                                                                                                                          

  Chemical compound,\           Sulfo-NHS-LC-Biotin           Thermo                     Cat.\                                                                    
  drug                                                                                   \#21335                                                                  

  Chemical compound,\           Pierce\                       Thermo                     Cat. \#29200                                                             
  drug                          NeutrAvidin Agarose                                                                                                               

  Chemical compound,\           cOmplete, Mini,\              Roche                      Cat. \#04693159001                                                       
  drug                          EDTA-free Proteinase\                                                                                                             
                                Inhibitor Cocktail                                                                                                                

  Chemical compound,\           BM-Purple AP substrate\       Sigma-Aldrich              Cat. \#11442074001                                                       
  drug                          Roche                                                                                                                             

  Chemical compound,\           G418                          Biochrom                   Cat. \#291--25                                                           125 μg/ml
  drug                                                                                                                                                            

  Chemical compound,\           HAT                           Gibco                      Cat. \#31062--037                                                        1:300
  drug                                                                                                                                                            

  Chemical compound,\           HT                            Gibco                      Cat. \#11067030                                                          1:100
  drug                                                                                                                                                            

  Chemical compound,\           Tunicamycin                   Sigma-Aldrich              Cat. \#T7765                                                             1 μg/ml
  drug                                                                                                                                                            

  Chemical compound,\           Alcian blue                   Sigma-Aldrich              Cat. \#A5268                                                             5% working solution
  drug                                                                                                                                                            

  Chemical compound, drug       Alizarin red                  Sigma-Aldrich              Cat. \#A5533                                                             5% working solution

  Other                         WesternBright\                Advansta                   Cat. \#12042-D20                                                         as recommended\
                                Quantum\                                                                                                                          by the manufacturer
                                HRP substrate                                                                                                                     

  Other                         Amersham ECL\                 GE Healthcare Life\        Cat. \#RPN2106                                                           as recommended by\
                                Detection\                    Sciences                                                                                            the manufacturer
                                Reagent                                                                                                                           

  Sequence-based\               DLL1 wt For                   other                      NA                                                                       5'-CTGAAGCGACCT\
  reagent                                                                                                                                                         GGCCCTGATAGCAC-3'

  Sequence-based\               DLL1 wt Rev                   other                      NA                                                                       5'-GGAGCTCCAGA\
  reagent                                                                                                                                                         CCTGCGCGGG-3'

  Sequence-based\               *Dll1^lacZ^* For              other                      NA                                                                       5'-ATCCCTGGGT\
  reagent                                                                                                                                                         CTTTGAAGAAG-3'

  Sequence-based\               *Dll1^lacZ^* Rev              other                      NA                                                                       5'-TGTGAGCGAGTA\
  reagent                                                                                                                                                         ACAACCCGTCGGATT-3'

  Sequence-based\               *Dll1^Dll1ki^* For            other                      NA                                                                       5'-GGTTTGGGGAT\
  reagent                                                                                                                                                         CCATAACTTCG-3'

  Sequence-based\               *Dll1^Dll1ki^* Rev            other                      NA                                                                       5'-GCCAGTCAGTTC\
  reagent                                                                                                                                                         CCAGTAAGAAGTC-3'\

  Sequence-based\               *Dll1^Dll4ki^* For            other                      NA                                                                       5'-AAGGACAACC\
  reagent                                                                                                                                                         TAATCCCTGCCG-3'

  Sequence-based\               *Dll1^Dll4ki^* Rev            other                      NA                                                                       5'-TGCCACATCG\
  reagent                                                                                                                                                         CTTCCATCTTAC-3'

  Sequence-based\               *Dll1^loxP^* For              other                      NA                                                                       5'-GCATTTCTCAC\
  reagent                                                                                                                                                         ACACCTC-3'

  Sequence-based\               *Dll1^loxP^* Rev              other                      NA                                                                       5'-GAGAGTACTT\
  reagent                                                                                                                                                         GATGGAGCAAG-3'

  Sequence-based\               *T(s):Cre* For                other                      NA                                                                       5'-AATCTTTGG\
  reagent                                                                                                                                                         GCTCCGCAGAG-3'

  Sequence-based\               *T(s):Cre* Rev                other                      NA                                                                       5'-ACGTTCACCGGC\
  reagent                                                                                                                                                         ATCAACG-3'

  Sequence-based\               *ZP3:Cre* For                 other                      NA                                                                       5'-GCCTGCATTACC\
  reagent                                                                                                                                                         \
                                                                                                                                                                  GGTCGATGCAACGA-3'

  Sequence-based\               *ZP3:Cre Rev*                 other                      NA                                                                       5'-GTGGCAGATGGC\
  reagent                                                                                                                                                         GCGGCAACACCATT-3'

  Sequence-based\               *Hprt-CAGD1ECD\_*\            this paper                 NA                                                                       5'-CCTAGCCCCTGCA\
  reagent                       *D4ICD + neo* For                                                                                                                 AGAACGGAGC-3'

  Sequence-based\               *Hprt-CAGD1ECD\_*\            this paper                 NA                                                                       5'-TTGCCACAATTG\
  reagent                       *D4ICD + neo* Rev                                                                                                                 GACTTGTC-3'

  Sequence-based\               *Hprt-CAGD4ECD\_*\            this paper                 NA                                                                       5'-CACTGTGAGCAT\
  reagent                       *D1ICD + neo* For                                                                                                                 AGTACC TTGAC-3'

  Sequence-based\               *Hprt-CAGD4ECD\_*\            this paper                 NA                                                                       5'-CATGGTTTCTGTCT\
  reagent                       *D1ICD + neo* Rev                                                                                                                 CTCCCCCACAGGG-3'

  Sequence-based\               *Hprt^D1ECD_D4ICDrec^*\       this paper                 NA                                                                       5'-ACATGGCCGTCATC\
  reagent                       and *Hprt^D4ECD_D1ICDrec^*\                                                                                                       AAAGAG-3'
                                For (activated allele)                                                                                                            

  Sequence-based\               *Hprt^D1ECD_D4ICDrec^*\       this paper                 NA                                                                       \
  reagent                       and *Hprt^D4ECD_D1ICDrec^*\                                                                                                       5'-GGGCAACAGAGA\
                                Rev (activated allele)                                                                                                            AATATCCTGTCTC-3'

  Sequence-based\               *Dll1^D1N-E3_D4ki^* For       this paper                 NA                                                                       5'-CTGTCTGCCAGG\
  reagent                                                                                                                                                         GTGTGATGACCAAC-3'

  Sequence-based\               *Dll1^D1N-E3_D4ki^* Rev       this paper                 NA                                                                       5'-ATCGCTGATG\
  reagent                                                                                                                                                         TGCAGTTCACA-3'

  Sequence-based\               *Dll1^D1N-E3_D4ki^* For       this paper                 NA                                                                       5'-TGCAGGAG\
  reagent                                                                                                                                                         TTCGTCAACAAG-3'

  Sequence-based\               *Dll1^D1N-E3_D4ki^* Rev       this paper                 NA                                                                       5'-ATAGTGGCC\
  reagent                                                                                                                                                         AAAGTGGTCATC\
                                                                                                                                                                  CCGAGGCTT-3'

  Sequence-based\               Y-Chromosome For              other                      NA                                                                       \
  reagent\                                                                                                                                                        5'-CTGGAGCTCT\
                                                                                                                                                                  ACAGTGATGA-3'

  Sequence-based\               Y-Chromosome Rev              other                      NA                                                                       5'-CAGTTACCAA\
  reagent                                                                                                                                                         TCAACACATCAC-3'

  Sequence-based\               *mNotch1* For                 other                      NA                                                                       5'-TAGGTGCTC\
  reagent                                                                                                                                                         TTGCGTCACTTGG-3'

  Sequence-based\               *mNotch1* Rev                 other                      NA                                                                       5'-TCTCCCCACT\
  reagent                                                                                                                                                         CGTTCTGATTGTC-3'

  Sequence-based\               *hNOTCH1* For                 PMID: 22002304;\           NA                                                                       5'-TCCACCAG\
  reagent                                                     DOI: 10.1038/onc\                                                                                   TTTGAATGGTCA-3'
                                                              .2011.467                                                                                           

  Sequence-based\               *hNOTCH1* Rev                 PMID: 22002304;\           NA                                                                       5'-AGCTCATCA\
  reagent                                                     DOI: 10.1038/onc.\                                                                                  TCTGGGACAGG-3'
                                                              2011.467                                                                                            

  Sequence-based\               *hNOTCH2* For                 this paper                 NA                                                                       5'-CAACCGCCA\
  reagent                                                                                                                                                         GTGTGTTCAAG-3'\

  Sequence-based\               *hNOTCH2* Rev                 this paper                 NA                                                                       5'-GAGCCATG\
  reagent                                                                                                                                                         CTTACGCTTTCG-3'

  Sequence-based\               *hNOTCH3* For                 PMID: 16327489;\           NA                                                                       5'-AGATTCTCA\
  reagent                                                     PMCID: PMC1409885                                                                                   TCCGAAACCGCTCTA-3'

  Sequence-based\               *hNOTCH3* Rev                 PMID: 16327489;\           NA                                                                       5'-GGGGTCTC\
  reagent                                                     PMCID: PMC1409885                                                                                   CTCCTTGCTATCCTG-3'

  Sequence-based\               *hGAPDH* For                  PMID: 22002304;\           NA                                                                       5'-GAGTCAACG\
  reagent                                                     DOI: 10.1038/onc.\                                                                                  GATTTGGTCGT-3'
                                                              2011.467                                                                                            

  Sequence-based\               *hGAPDH* Rev                  PMID: 22002304;\           NA                                                                       5'-TTGATTTTGG\
  reagent                                                     DOI: 10.1038/onc.\                                                                                  AGGGATCTCG-3'
                                                              2011.467                                                                                            

  Sequence-based\               Forward primer -\             other                      NA                                                                       5'-GGGAACCTGTT\
  reagent                       correct integration\                                                                                                              AGAAAAAAAGA\
                                into *Hprt* locus                                                                                                                 AACTATGAAGAAC-3'

  Sequence-based\               Reverse primer -\             other                      NA                                                                       5'-GGCTATGAACTAATG\
  reagent                       correct integration\                                                                                                              GACCCCG-3'
                                into *Hprt* locus                                                                                                                 

  Sequence-based\               Forward primer\               other                      NA                                                                       5'-TGTCACGT\
  reagent                       - correct integration\                                                                                                            CCTGCACGACG-3'
                                into *Dll1* locus                                                                                                                 

  Sequence-based\               Reverse primer -\             other                      NA                                                                       5'-GGTATCGGA\
  reagent                       correct integration\                                                                                                              TGCACTCATCGC-3'
                                into *Dll1* locus                                                                                                                 

  Sequence-based\               guideA-For                    this work,\                NA                                                                       5\'-GGCAGCGGG\
  reagent                                                     according to\                                                                                       CAGCTCCGGAT-3\'
                                                              <http://crispr.mit.edu/>                                                                            

  Sequence-based\               guideB-Rev                    this work, according to\   NA                                                                       5\'-GCTCTCGGG\
  reagent                                                     <http://crispr.mit.edu/>                                                                            GTCGTCGCTGC-3\'

  Recombinant DNA\              Uncx-probe (plasmid)          DOI 10.1007/\                                                                                       
  reagent                                                     s004270050120                                                                                       

  Recombinant DNA\              pLexM (plasmid)               DOI 10.1074/\                                                                                       
  reagent                                                     jbc.M113.454850                                                                                     

  Recombinant DNA\              Cas9 D10A\                    DOI 10.1126/\              Addgene \#42335                                                          
  reagent                       nickase (plasmid)             science.1231143                                                                                     

  Recombinant DNA\              *Dll1* 5\' SB probe           PMID: 26801181;\                                                                                    5' probe: a 316 bp BamHI/AvaII\
  reagent                                                     PMCID: PMC4788113;\                                                                                 fragment 3.8 kb upstream\
                                                              DOI: 10.1534/genetics.\                                                                             of *Dll1* exon 1\
                                                              115.184515                                                                                          

  Recombinant DNA\              *Dll1* 3\' SB probe           PMID: 26801181;\                                                                                    3' probe: a 528 bp PCR\
  reagent                                                     PMCID: PMC4788113;\                                                                                 fragment in *Dll1*\
                                                              DOI: 10.1534/genetics.\                                                                             intron five obtained\
                                                              115.184515                                                                                          with primers CCTGTGAGACTTTCTA\
                                                                                                                                                                  CGTTGCTC/CACAACCATGTCA\
                                                                                                                                                                  CCTTCTAGATTC

  Software,\                    ImageJ; FIJI                                             RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)             ISAC Manager
  algorithm                                                                                                                                                       

  Software,\                    Prism                         GraphPad                   RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)             
  algorithm                                                                                                                                                       

  Software,\                    Olympus                       Olympus FLUOVI\            RRID:[SCR_014215](https://scicrunch.org/resolver/SCR_014215)             
  algorithm                                                   EW FV1000                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation and husbandry of transgenic mice {#s4-1}
-------------------------------------------

### Ethics statement {#s4-1-1}

All animal experiments were performed according to the German rules and regulations (Tierschutzgesetz) and approved by the ethics committee of Lower Saxony for care and use of laboratory animals LAVES (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit; refs.: 33.12-42505-04-13/1314 and 33.14-42505-04-13/1293). Mice were housed in the central animal facility of Hannover Medical School (ZTL) and were maintained as approved by the responsible Veterinary Officer of the City of Hannover. Animal welfare was supervised and approved by the Institutional Animal Welfare Officer (Tierschutzbeauftragter).

### Mouse strains {#s4-1-2}

Wild type mice were CD1 and 129Sv/CD1 hybrids; *Dll1^lacZ^* ([@bib20]), *Dll1^loxP^* ([@bib19]), T(s):Cre ([@bib16]) and ZP3:Cre ([@bib14]), *Dll1^Dll1ki^* ([@bib43]), and *Dll1^Dll4ki^* ([@bib38]) were described previously.

### Generation of transgenic mice {#s4-1-3}

Mice allowing for inducible expression of chimeric ligands were generated by morula injection of E14TG2a ES cells carrying the expression construct in the *Hprt* locus. E14TG2a cells were electroporated with linearized targeting constructs and correct integrations were identified by HAT selection and validated by long-range PCR using primers: For/Rev: GGGAACCTGTTAGAAAAAAAGAAACTATGAAGAAC/GGCTATGAACTAATGACCCCG.

*Dll1^D1N-E3_D4ki^* and *Dll1^D1contD4ki^* mice were generated with 129Sv/cast ES cells. ES cells were electroporated with linearized targeting constructs, Cas9 D10A nickase (Addgene \#42335; [@bib11]) expression vector and guide RNAs targeting the first intron of *Dll1* to increase the frequency of homologous recombination (guideA-FOR: GGCAGCGGGCAGCTCCGGAT; guideB-REV: GCTCTCGGGGTCGTCGCTGC, according to <http://crispr.mit.edu/> the pair score for A and B -- 79, 0 off target pairs, and 0 genic OT pairs). G418 resistant clones were screened for targeted integrations by long-range PCR using primers: For/Rev TGTCACGTCCTGCACGACG/GGTATCGGATGCACTCATCGC and correct targeting events verified by Southern blot analysis (5' probe: a 316 bp BamHI/AvaII fragment 3.8 kb upstream of *Dll1* exon 1; 3' probe: a 528 bp PCR fragment in *Dll1* intron five obtained with primers CCTGTGAGACTTTCTACGTTGCTC/CACAACCATGTCACCTTCTAGATTC). The *neo^r^* cassette was excised in the female germ line using ZP3:Cre mice.

### Genotyping of mice and embryos {#s4-1-4}

Genomic DNA was isolated from ear or tail biopsies, yolk sacs or umbilical cords and used as template in PCRs with the following primer pairs: *Hprt^Dll1ECD_Dll4ICD^* For/Rev CTGTCTGCCAGGGTGTGATGACCAAC/CAGATTGTTCATGGCTTCCCT; *Hprt^Dll4ECD_Dll1ICD^* For/Rev CACTGTGAGCATAGTACCTTGAC/CATGGTTTCTGTCTCTCCCCCACAGGG; *Hprt^Dll1ECD_Dll4ICDrec^* or *Hprt^Dll4ECD_Dll1ICDrec^* (activated alleles) For/Rev ACATGGCCGTCATCAAAGAG/GGGCAACAGAGAAATATCCTGTCTC; *Dll1^loxP^* For/Rev GCATTTCTCACACACCTC/GAGAGTACTTGATGGAGCAAG; T(s):Cre For/Rev AATCTTTGGGCTCCGCAGAG/ACGTTCACCGGCATCAACG; ZP3:Cre For/Rev GCCTGCATTACCGGTCGATGCAACGA/GTGGCAGATGGCGCGGCAACACCATT; *Dll1^wt^* For/Rev CTGAAGCGACCTGGCCCTGATAGCAC/GGAGCTCCAGACCTGCGCGGG; *Dll1^lacZ^* For/Rev ATCCCTGGGTCTTTGAAGAAG/TGTGAGCGAGTAACAACCCGTCGGATT; *Dll1^Dll4ki^* For/Rev AAGGACAACCTAATCCCTGCCG/TGCCACATCGCTTCCATCTTAC; *Dll1^Dll1ki^* For/Rev GGTTTGGGGATCCATAACTTCG/GCCAGTCAGTTCCCAGTAAGAAGTC; *Dll1^D1N^*^-*E3_D4ki*^ For/Rev CTGTCTGCCAGGGTGTGATGACCAAC/ATCGCTGATGTGCAGTTCACA; *Dll1^D1contD4ki^* For/Rev TGCAGGAGTTCGTCAACAAG/ATAGTGGCCAAAGTGGTCATCCCGAGGCTT; Y-chromosome PCR For/Rev CTGGAGCTCTACAGTGATGA/CAGTTACCAATCAACACATCAC

### Cloning of constructs {#s4-1-5}

#### *Hprt* targeting constructs for expression from single copy integrations in ES cells {#s4-1-5-1}

cDNAs encoding Flag-tagged ligand proteins with exchanges of domains or individual amino acids in the extracellular domain of DLL1 and DLL4 were generated by standard cloning procedures using either synthesized gene fragments (II-IV, VII-IX, XI-XIII in [Figure 1](#fig1){ref-type="fig"}) or fragments obtained by restriction digests from *Dll1* and *Dll4* cDNA constructs (V, X in [Figure 1](#fig1){ref-type="fig"}). Tagged cDNAs were cloned into pMP8-CAG.Stop-shuttle as *EcoR*I/*BamH*I or *EcoR*I/*Not*I fragments. The stop cassette was excised by Cre mediated recombination of the *loxP* sites in bacterial SW106 cells.

#### *Hprt* targeting constructs for inducible expression in transgenic mice {#s4-1-5-2}

D1*ECD*\_D4*ICD* and D4*ECD*\_D1*ICD* were generated by PCR amplification of the respective untagged cDNAs and subcloned into shuttle vector pSL1180dttomato containing the wild type and mutant *loxP* sites and iresdsRED. Subsequently, the fragments encoding the chimeric ligands fused to iresdsRED were cloned into pMP8-CAG.Stop ([@bib38]) using *Mlu*I and *Swa*1 restriction sites.

#### Mini gene constructs for targeting the *Dll1* locus {#s4-1-5-3}

*Dll1^D1N-E3_D4ki^* and *Dll1^D1contD4ki^* targeting constructs were generated by standard cloning procedures based on the *Dll1^Dll1ki^* (*Dll1^tm7.1Gos^*) or *Dll1^Dll4ki^* (*Dll1^tm4.1Gos^)* targeting vectors ([@bib38]; [@bib43]). First, the 3' DT cassette was removed by *Pme*I and *Aat*II digest and relegation of the blunt ended plasmid. EcoRI fragments containing the *Dll1* or *Dll4* coding sequences in the targeting vector lacking the 3' DT cassette were excised by *EcoR*I and cloned into pCR-TOPO-XL. The wild type *Dll1* sequence was replaced in pCR-TOPO-XL by a D1contD4 cDNA, the *Dll4* sequence by D1*N-E3*\_D4 cDNA. Fragments were ligated back into the targeting vectors as *EcoR*I fragments.

#### Avi-His-tagged ligand fragments for protein expression and purification {#s4-1-5-4}

For production and purification of proteins for binding assays (XIV-XVIII in [Figure 1](#fig1){ref-type="fig"}) fragments encompassing the N-terminus up to and including EGF5 were PCR amplified and cloned into pLexM-Avi-His vector ([@bib1]) as *EcoR*I/*BamH*I fragments by standard procedures.

Analysis of gene expression patterns and phenotypes {#s4-2}
---------------------------------------------------

### Whole mount in situ hybridization {#s4-2-1}

E9.5 embryos were collected in ice cold PBS and fixed in 4% formaldehyde/PBS over night at 4°C and dehydrated in methanol. In situ hybridization was performed according to standard procedures with digoxigenin labelled cDNA probes for *Uncx* ([@bib35]).

### Antibody staining {#s4-2-2}

E18.5 embryos were collected in ice cold PBS, fixed in 4% formaldehyde/PBS over night at 4°C, dehydrated in methanol, ethanol, and 2-propanol. Hind limbs were paraffin embedded and 10 µm transverse sections stained for Myosin Heavy Chain (MHC).

### Whole mount immunofluorescence {#s4-2-3}

E9.5 embryos were collected in ice cold PBS, fixed in 4% formaldehyde in PBS and immunofluorescence staining was performed as described in [@bib5]. Used primary antibodies: anti-DLL1 (1F9; 1:50) ([@bib17]), anti-DLL4 (AF1389, R and D; 1:50), and anti-pan-Cadherin (C1821, Sigma; 1:250). Used secondary antibodies: Alexa488/555 conjugated antibodies (Invitrogen; 1:100). Images were taken using OLYMPUS FV1000.

### Skeletal preparations {#s4-2-4}

E15.5 fetuses were collected in ice cold PBS and dehydrated in EtOH. Alcian blue and Alizarin red staining was performed using standard procedures ([@bib12]).

### Western blot analyses {#s4-2-5}

Cells were lysed in 2x sample buffer (0.125M Tris pH 6.8; 4% SDS; 20% glycin; 5% β-mercaptoethanol; 0.025% bromphenol blue). Proteins were separated by SDS-PAGE and transferred onto Immobilon-P Transfer membranes (Millipore) by wet tank or SemiDry blotting. Membranes were blocked in 5% nonfat dried milk powder (AppliChem) in PBS/0.1% Tween20 and subsequently incubated in 5% nonfat dried milk powder containing primary antibodies. Used primary antibodies: anti-Flag HRP (mouse monoclonal; clone M2; Sigma; 1:10 000), anti-b-Tubulin I (Sigma; 1:500 000/1:1 000 000). Used secondary antibodies: anti-mouse HRP (Amersham; 1:10 000). For HRP detection ECL Western Blotting Detection Reagent (Amersham) and WesternBright Quantum (advansta) were used with Luminiscent Image Analyser LAS4000 (Fujifilm). ImageJ was used to quantify signals.

### RT-PCR {#s4-2-6}

HeLaN1 cells were lysed in Tri-Reagent (Sigma) and RNA was isolated according to the manufacturer's instructions. Reverse transcription was performed using SuperScript IV (Invitrogen) according to the manufacturer's instructions. Primers used for RT-PCR analysis were: *mNotch1* For/Rev TAGGTGCTCTTGCGTCACTTGG/TCTCCCCACTCGTTCTGATTGTC; *hNOTCH1* For/Rev TCCACCAGTTTGAATGGTCA/AGCTCATCATCTGGGACAGG ([@bib15]); *hNOTCH2* For/Rev CAACCGCCAGTGTGTTCAAG/GAGCCATGCTTACGCTTTCG; *hNOTCH3* For/Rev AGATTCTCATCCGAAACCGCTCTA/GGGGTCTCCTCCTTGCTATCCTG ([@bib8]); *hGAPDH* For/Rev GAGTCAACGGATTTGGTCGT/TTGATTTTGGAGGGATCTCG ([@bib15]).

### Southern blot analyses {#s4-2-7}

Genomic DNA was isolated from ES cells, digested with BamHI overnight and separated on an 0.7% agarose gel. Blotting, crosslinking, hybridization, and signal detection were performed using Immobilon-Ny+ membrane (Millipore) according to the manufacturer's instructions.

Cell culture experiments {#s4-3}
------------------------

### Culture of cells {#s4-3-1}

Mouse E14TG2a and 129Sv/cast ES cells were cultured in DMEM (Invitrogen) cell culture medium supplemented with 15% FCS (Biochrom AG), Glutamax, Pen/Strep, Sodium Pyruvate, MEM Non-Essential Amino Acid Solution, β-mercaptoethanol, and leukemia inhibitory factor (LIF), HeLaN1 cells were cultured in DMEM (Invitrogen) cell culture medium supplemented with 10% FCS (Biochrom AG), Glutamax and Pen/Strep. All cell lines were tested negative for mycoplasma. No authentication of cell lines was performed.

### Generation of cells stably expressing ligand proteins {#s4-3-2}

ES cells were electroporated with linearized pMP8 targeting vectors and selected with HAT (1:300; Gibco). Correct integration of the 5' homology arm in HAT resistant clones was verified with long-range PCR using following primers: For/Rev: GGGAACCTGTTAGAAAAAAAGAAACTATGAAGAAC/GGCTATGAACTAATGACCCCG. Expression of proteins was verified using Western Blot analyses.

### Trans-activation assay {#s4-3-3}

For in vitro cell co-culture assays ES cells were counted in PBS using LUNA-II (logos biosystems) and 9.25 × 10^5^ ligand and 0.75 × 10^5^ receptor expressing cells were plated on gelatin coated six well plate dishes. After 24 hr fresh medium was added. 48--52 hr after co-cultivation cells were washed once with PBS, lysed in 250 µl 1xCCLR (Luciferase Cell Culture Lysis Reagent, Promega), transferred into 1.5 ml tubes, and frozen at −80°C. For measurements lysates were thawed, vortexed, and briefly centrifuged. 20 µl aliquots of each lysate was measured with Luciferase Assay Reagent in duplicates or quadruplicates using GloMax-96 (Promega).

### Biotinylation assay {#s4-3-4}

For determination of relative cell surface protein levels, cells were treated with Sulfo-NHS-LC-Biotin (Pierce; 0.25 mg/ml PBS supplemented with 1 mM MgCl~2~ and 0.1 mM CaCl~2~), quenched with 100 mM glycine in DMEM and lysed in lysis buffer supplemented with Complete Proteinase Inhibitor Cocktail Tablets (Roche). Biotinylated proteins were immunoprecipitated using NeutrAvidin beads (Thermo Scientific) and analyzed by Western blotting. For detailed information see ([@bib6]; [@bib38]).

### Protein expression and purification {#s4-3-5}

The cDNA for expression of the N1 fragment using the pLexM vector was described previously ([@bib1]) and encodes the N1 signal sequence followed by EGF repeats 6--15 (amino acids 216--604), a biotinylation (avi) tag, and a His~6~ tag. The cDNAs for expression of DLL1, DLL4, and all chimeric proteins extend from the N-terminus through EGF5. These proteins were also subcloned into pLexM as described ([@bib1]). The N2(1--15)-Fc protein was purchased from R and D systems and used without further purification.

Expi293F cells maintained in Expi293 expression media were grown to cell density of 10^6^ cells/ml and then transiently transfected with *Dll1* ligand, *Dll4* ligand or *N1* DNA (1 mg/liter of cells) and FectoPro transfection reagent (Polyplus) at 1:1 DNA/FectoPro ratio. For biotinylation of Avi-tagged NOTCH1 protein, cells were co-transfected with biotin ligase (BirA) DNA as well as with DNA encoding Protein O-fucosyltransferase-1 (POFUT1), which enhances Notch folding and secretion.

Transfected cells were then cultured in FreeStyle293 media for 3--4 days to produce protein. The media was collected, separated from the cells by centrifugation and supplemented with 50 mM Tris buffer, pH 8.0. The resulting supernatant was bound to Ni-NTA beads (Qiagen) over a 3 hr incubation at 4° C. After a wash with ten column volumes of 50 mM Tris buffer, pH 8.0, containing 150 mM NaCl, 5 mM CaCl~2~, and 20 mM Imidazole, bound protein was eluted with the same buffer supplemented with 250 mM Imidazole. Following elution, fractions containing the partially purified proteins were concentrated and further purified by gel-filtration chromatography using a Superdex 200 column in 50 mM Tris, pH 8.0, containing 150 mM NaCl, and 5 mM CaCl~2~. The quality of the resulting purified proteins was assessed using non-reducing SDS-PAGE. Pure fractions were pooled, flash frozen and stored at −80° C. The efficiency of biotinylation was estimated by immunoprecipitation with streptavidin resin.

### Biolayer interferometry {#s4-3-6}

Ligand binding affinities were quantified by biolayer interferometry using a BLItz instrument (ForteBio). For N1 binding, streptavidin biosensors were loaded with the biotinylated Notch1 fragment, equilibrated in buffer for 30 s, then dipped into ligand samples of varying concentration until equilibrium was observed. For N2 binding, protein A biosensors were used for the capture step. All ligand-receptor binding experiments were done in HBS-P buffer containing 0.005% surfactant P20, supplemented with 5 mM CaCl~2~. Equilibrium binding curves were fitted with a one site - specific binding model using GraphPad Prism.

### Statistical analysis {#s4-3-7}

Statistical analyses were done using Prism7 (GraphPad) as indicated in Figure legends.
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Animal experimentation: All animal experiments were performed according to the German rules and regulations (Tierschutzgesetz) and approved by the ethics committee of Lower Saxony for care and use of laboratory animals LAVES (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit; refs.: 33.12-42502-04-13/1314 and 33.14-42502-04-13/1293). Mice were housed in the central animal facility of Hannover Medical School (ZTL) and were maintained as approved by the responsible Veterinary Officer of the City of Hannover. Animal welfare was supervised and approved by the Institutional Animal Welfare Officer (Tierschutzbeauftragter).
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###### Relative cell surface expression levels of the ligand proteins used co-culture studies.

Levels of one representative clone for each ligand protein were determined by cell surface biotinylation and quantitative analysis of Western blots after immunoprecipitation. Values for DLL1 and DLL4 see [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}. ND: due to closely co-migrating background band protein levels could not be quantified. Surface expression validated by biotinylation of ES cells and antibody staining of PSMs.

10.7554/eLife.40045.025

###### Relative ligand protein expression level in ES cell clones.

The protein level of three independent clones used for co-culture studies was determined by quantitative analysis of Western blots and normalized to DLL1 clone \#1 protein level measured in the same assay. Values for DLL1 and DLL4 see [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}. ND: due to closely co-migrating background band protein levels could not be quantified.

10.7554/eLife.40045.026

Data availability {#s7}
-----------------

All data generated or analysed during this study are included in the manuscript and supporting files and source data files.
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Decision letter

Lendahl

Urban

Reviewing Editor

Karolinska Institute

Sweden

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Urban Lendahl as Reviewing Editor and Didier Stainier as Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Thomas Gridley (Reviewer \#1); Rhett A Kovall (Reviewer \#2); Cecilia Sahlgren (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript addresses the important question of ligand-receptor specificity in the Notch signaling pathway. The authors describe structure-function analyses, and functional divergence, of the Notch ligands DLL1 and DLL4, using in vivo as well as in vitro techniques. The authors conclude that the DLL1 and DLL4 proteins activate the Notch1 and Notch2 receptors differently. DLL4 consistently activated NOTCH1 significantly better than DLL1, and DLL4 stimulated Notch2 significantly less efficiently than DLL1.To identify the domains of DLL1 and DLL4 that contributed to the observed differences in activating Notch1 and Notch2, domain swaps to generate a set of chimeric DLL1/DLL4 ligands was performed. These experiments revealed that the differences in activation potential of DLL4 and DLL1 toward Notch1 and Notch2 are encoded in the N-terminal part of the protein, comprising the MNNL-EGF3 domains, but also with a contribution from the third EGF repeat. This is interesting, as these regions lie outside the established receptor-ligand interaction domains.

Essential revisions:

1\) In the Abstract the authors state, \"Collectively, our data show that DLL4 and DLL1 preferentially activate NOTCH1 and NOTCH2, respectively,\"; however, the N1/N2 ratio data in Figure 5A suggest that DLL1 has no preference for Notch1 over Notch2. Please clarify.

2\) In the last paragraph of the subsection "Regions outside the known receptor binding domain are essential for full DLL1 function in vivo", the authors use the word \"undistinguishable\", do the authors mean indistinguishable?

3\) Regarding the in vivo data where different chimeras are used to substitute for DLL1 there appears to be additional staining or even puncta for the ligand, e.g. Figure 2Cd, Figure 3Cdfgi, Figure 6Bfh, that is not at the cell surface and is not seen in the wild-type tissues. Could the authors provide some explanation as to what this additional staining is and do they think that this accumulated ligand has any effect on the phenotypes that they are seeing?

4\) In Figure 3Fc do the authors mean Dll1Dll4ki/Dll4ki rather than Dll1Dll1ki/Dll1ki as currently stated?

5\) In Figure 5B, I would suggest that the authors label the domains of Notch1, Dll4, and Dll1 on the structures to clarify these regions for the reader who is not a structural biologist.

6\) Figure 4E and F. Showing both black dots and triangles in the same graph is confusing.

7\) Figure 5 and subsection "The region encompassing the MNNL up to and including EGF3 encodes the differential receptor selectivity of DLL1 and DLL4" MNNL-DSL (D1N-D_D4 & D4N-D_D1) values don\'t look intermediate but as low (if not lower) than D1N-E3_D4 -- rephrase?

8\) Discussion, second paragraph -- D1ECD_D4ECD changed to D1ECD_D4ICD.

9\) Much of the data (protein-protein levels, membrane levels and signalling activity) from the co-culture signalling studies are adjusted to a data point set to 1 and many of the analyses are further related to this reference value which is an average. There is high variability and the original data was not shown and the number of analyses were very high. I would like to see the original data, ask for a comparison between membrane levels, total protein levels and signal activity within a set of experiments to avoid making erroneous conclusions based on statistical \"engineering\"

10\) Figure 4C, E and F Why only n=1 in Dll1? Does that represent the average? What is the variability?

11\) Figure 5. Showing the N1 and N2 stimulations and not only the ratio could add some clarity (Despite varying membrane levels). Perhaps a supplementary figure?

12\) Figure 5. How come D1N-E3 gives such a strong signal in reporter assays if it is not detectable/quantifiable on WB or biotinylation assay? Could you provide the image of the WB for assurance?

13\) The chimeric ligand is expressed more efficiently than the endogenous one (Figure 3C). Could this affect the result?

The full reviews are also included for your reference, as they contain detailed and useful suggestions.

*Reviewer \#1:*

The authors describe structure-function analyses, and functional divergence, of the Notch ligands DLL1 and DLL4, using cell co-culture assays, biochemical assays, and in vivo analyses of genetically modified mice expressing recombinant DLL1/DLL4 chimeric proteins. The authors demonstrate that, in cell based co-culture assays, the DLL1 and DLL4 proteins activate the NOTCH1 and NOTCH2 receptors differently. They generated mouse NOTCH1 and NOTCH2 reporter ES cell lines by integrating a Notch luciferase reporter in the Hprt locus of mouse E14TG2a ES (E14) cells, thus generating stable mN1 (N1rep) or mN2 (N2rep) reporter lines. These reporter lines were then co-cultured with ES cells with single copy integrations into the Hprt locus of the DLL1 or DLL4 coding sequences. Performing careful controls for total protein and cell surface protein expression levels, they showed that all DLL4 clones consistently activated N1 significantly better than all DLL1 clones, and all DLL4 clones stimulated mN2 significantly less efficiently than DLL1. To identify the domains of DLL1 and DLL4 that contributed to the observed differences in activating NOTCH1 and NOTCH2, they performed a series of domain swaps to generate a set of chimeric DLL1/DLL4 ligands. These experiments revealed that the differences in activation potential of DLL4 and DLL1 toward N1 and N2 are encoded in the N-terminal part of the protein, comprising the MNNL-EGF3 domains. Additional experiments showed that the third EGF repeat made an important contribution to receptor selectivity.

The authors then analyzed the importance of the amino acids that contact N1 in the binding interfaces of the MNNL and DSL domains in NOTCH receptor selectivity. In a series of biochemical experiments, the authors showed that swapping the contact residues of DLL4 onto DLL1 did not substantially affect Notch receptor activation compared to wildtype DLL1. Replacement of the DLL4 contact residues by the analogous residues of DLL1 slightly affected Notch receptor activation, but did not approach the activity difference of wildtype DLL1.

For in vivo analyses, the authors utilized a sophisticated genetic model system in which transgenes encoding chimeric DLL1/DLL4 ligands were introduced into the Hprt locus of E14 ES cells in a manner that requires Cre recombinase expression to permit expression of the chimeric ligand. Simultaneously, endogenous wildtype DLL1 expression was removed using a floxed Dll1 allele and a Cre driver (T(s):Cre) expressed in the primitive streak driven by a promoter derived from brachyury (T) locus. These experiments demonstrated that the extracellular domains of the DLL1 and DLL4 ligands regulated ligand function during somite formation. The authors then tested a chimeric ligand that contained the N-terminal region up to and including EGF3 of DLL1 fused to EGF4 and the remaining C-terminal portion of DLL4. Mice homozygous for this allele (and lacking the wildtype Dll1 allele) were still born and exhibited substantial axial skeletal defects, indicating that this chimeric allele cannot fully replace wildtype DLL1 function during development.

These experiments, as is characteristic of all the work from the Gossler and Blacklow laboratories, are carefully controlled, extremely thorough, and very convincing. This paper makes an important contribution to the literature on structure/function analysis of the Notch ligands.

*Reviewer \#2:*

The authors submit an interesting and compelling manuscript that focuses on using different in vivo and cellular assays to characterize the functional differences between Dll1 and Dll4. The work is of high quality and the manuscript is well written. Moreover, their findings address an important area of Notch signaling and biology in general, and impact other recent publications that characterize functional differences between Dll1/4. If the authors were to address my relatively minor comments summarized below, I would recommend their manuscript to be published *eLife*.

In the Abstract the authors state, \"Collectively, our data show that DLL4 and DLL1 preferentially activate NOTCH1 and NOTCH2, respectively,\"; however, the N1/N2 ratio data in Figure 5A suggest that DLL1 has no preference for Notch1 over Notch2. Please clarify.

In the last paragraph of the subsection "Regions outside the known receptor binding domain are essential for full DLL1 function in vivo", the authors use the word \"undistinguishable\", do the authors mean indistinguishable?

Regarding the in vivo data where different chimeras are used to substitute for DLL1 there appears to be additional staining or even puncta for the ligand, e.g. Figure 2Cd, Figure 3Cdfgi, Figure 6Bfh, that is not at the cell surface and is not seen in the wild-type tissues. Could the authors provide some explanation as to what this additional staining is and do they think that this accumulated ligand has any effect on the phenotypes that they are seeing?

In Figure 3Fc do the authors mean Dll1Dll4ki/Dll4ki rather than Dll1Dll1ki/Dll1ki as currently stated?

In Figure 5B, I would suggest that the authors label the domains of Notch1, Dll4, and Dll1 on the structures to clarify these regions for the reader who is not a structural biologist.

*Reviewer \#3:*

The work by Tveriakhina and colleagues addresses the biochemical rational behind the context dependent functional differences of Notch ligands. The in vivo evidence is strong and they nicely demonstrate context dependent contributions of Notch ligand extracellular EGF repeats in vivo. They further demonstrate, although the data raise some concerns, that Dll1 and Dll4 ligands exhibit different receptor selectivity and discriminate between Notch1 and Notch2 receptors and that this is caused by differences in ligand ECD domains outside the established receptor-ligand interaction domains (contact domains). The paper is well written, clear and concise. The data is well presented and for the most part support the conclusions. The work provides novel insight into the receptor-ligand interphase and presents protein regions that contribute to functional divergence of ligands and warrants publication, provided the authors address the concerns raised.

10.7554/eLife.40045.030

Author response

> Essential revisions:
>
> 1\) In the Abstract the authors state, \"Collectively, our data show that DLL4 and DLL1 preferentially activate NOTCH1 and NOTCH2, respectively,\"; however, the N1/N2 ratio data in Figure 5A suggest that DLL1 has no preference for Notch1 over Notch2. Please clarify.

Indeed, as the reviewer points out, DLL1 stimulates N1 and N2 (more-or-less) equally, whereas DLL4 preferentially activates NOTCH1 over NOTCH2. We have clarified this as follows:

"Collectively, our data show that DLL4 preferentially activates NOTCH1 over NOTCH2, whereas DLL1 is equally effective in activating NOTCH1 and NOTCH2, establish that the ectodomains dictate selective ligand function in vivo, and that features outside the known binding interface contribute to their differences."

In addition, to stay within the length limit we have slightly reworded the Abstract as indicated.

> 2\) In the last paragraph of the subsection "Regions outside the known receptor binding domain are essential for full DLL1 function in vivo", the authors use the word \"undistinguishable\", do the authors mean indistinguishable?

We changed "undistinguishable" to "indistinguishable".

> 3\) Regarding the in vivo data where different chimeras are used to substitute for DLL1 there appears to be additional staining or even puncta for the ligand, e.g. Figure 2Cd, Figure 3Cdfgi, Figure 6Bfh, that is not at the cell surface and is not seen in the wild-type tissues. Could the authors provide some explanation as to what this additional staining is and do they think that this accumulated ligand has any effect on the phenotypes that they are seeing?

The cytoplasmic staining of ligands including wt DLL1 (Figure 3Cjl and 6Bdh) reflects at least in part the presence of ligands in the ER and Golgi apparatus as has been shown previously by co-staining in cell lines (Geffers et al., 2007 and Müller et al., 2014) and has previously also been observed in the PSM (Preusse et al., 2015). We have added this information in the legend to Figure 2C as follows:

"Additional intracellular staining most likely reflects the presence of the ligand in the ER and trans Golgi as observed previously for DLL1 in cultured cells (Geffers et al., 2007; Müller et al., 2014) and for endogenous DLL1 and transgenic DLL4 in the PSM (Preusse et al., 2015)".

And the new citation (Müller et al., 2014) was added to the references.

> 4\) In Figure 3Fc do the authors mean Dll1Dll4ki/Dll4ki rather than Dll1Dll1ki/Dll1ki as currently stated?

We regret this error and have corrected the mislabeling.

> 5\) In Figure 5B, I would suggest that the authors label the domains of Notch1, Dll4, and Dll1 on the structures to clarify these regions for the reader who is not a structural biologist.

We have labelled the structures in revised Figure 5B as suggested and indicated the domains by different shadings.

> 6\) Figure 4E and F. Showing both black dots and triangles in the same graph is confusing.

We have changed Figure 4E and F (please see also point 9).

> 7\) Figure 5 and subsection "The region encompassing the MNNL up to and including EGF3 encodes the differential receptor selectivity of DLL1 and DLL4" MNNL-DSL (D1N-D_D4 & D4N-D_D1) values don\'t look intermediate but as low (if not lower) than D1N-E3_D4 -- rephrase?

We have rephrased the sentence to clarify that the chimeric pairs exhibit equivalent N1/N2 ratios as follows:

"When chimeras include the MNNL-EGF2 or MNNL-DSL region of one ligand and the remainder of the other, the N1/N2 stimulation ratios of the chimeric pairs are equivalent (Figure 5A), indicating that the third EGF-like repeat makes an important contribution to receptor selectivity."

> 8\) Discussion, second paragraph -- D1ECD_D4ECD changed to D1ECD_D4ICD.

This error has been corrected.

> 9\) Much of the data (protein-protein levels, membrane levels and signalling activity) from the co-culture signalling studies are adjusted to a data point set to 1 and many of the analyses are further related to this reference value which is an average. There is high variability and the original data was not shown and the number of analyses were very high. I would like to see the original data, ask for a comparison between membrane levels, total protein levels and signal activity within a set of experiments to avoid making erroneous conclusions based on statistical \"engineering\"

We have included the ratios of DLL1/TUB and DLL4/TUB determined by Western blot quantitation in Figure 4---source data 2 and show now an additional graph (in the revised Figure 4---figure supplement 1) depicting the values obtained from multiple technical replicates of the DLL1 and DLL4 clone done in parallel.

We also show in the revised Figure 4E and F the non-normalized N1 and N2 activation (RLU values minus background; previously only given in the tables in Figure 4---figure supplement 1---source data 2; now for clarity also in Figure 4---source data 4 and 5) from analyses done in parallel in addition to the normalized values. This representation shows that despite the variability between different co-cultures DLL4 consistently activates N1 better and N2 less efficiently than DLL1.

In addition we have expanded Figure 4 figure supplement 1 and show graphs for the technical replicates of all DLL1 (4) and DLL4 (10) clones.

Normalized values are presented in the right graphs of Figure 4E and F, and in the right graphs in Figure 4---figure supplement 1.

> 10\) Figure 4C, E and F Why only n=1 in Dll1? Does that represent the average? What is the variability?

The dot in Figure 4 C represented the "average" of 10 DLL1 measurements set to 1. Each DLL4 value was referenced to its paired DLL1 value, which was arbitrarily set to 1 for each measurement. As described for point 9 we have included now the original DLL/TUB ratios in Figure 4---source data 2 and Figure 4---figure supplement 1A.

> 11\) Figure 5. Showing the N1 and N2 stimulations and not only the ratio could add some clarity (Despite varying membrane levels). Perhaps a supplementary figure?

We followed this suggestion and have included new Figure 5---figure supplement 1 showing the relative luciferase activity measured in co-cultures.

> 12\) Figure 5. How come D1N-E3 gives such a strong signal in reporter assays if it is not detectable/quantifiable on WB or biotinylation assay? Could you provide the image of the WB for assurance?

D1N-E3 is detectable on WB and after biotinylation, but cannot be quantified with confidence due to a closely co-migrating background band detected by the anti-Flag antibodies. We have tried different polyacrylamide concentrations but could not separate the background band enough for reliable quantification. We include representative WBs (which could be added as a supplementary file if required) as [Author response image 1](#respfig1){ref-type="fig"}.

![Expression of D1*N-E3\_*D4 cannot be quantified with confidence due to a closely co-migrating background band detected by the anti-Flag antibody.\
(**A**) Expression of wild type DLL1 and DLL4 and of chimeric ligand proteins. Protein migration size varies due to differential post-translational modifications of the extracellular domains of DLL1 and DLL4. Double bands in DLL4, D4*ECD*\_D1/*CD*, D4*N-E3\_*D1, D4*N-E2*D1, and D4*N-D\_*D1 lysates represent most likely differential modification states of the DLL4's ECD. (**B**) D1*N-E3\_*D4 migrates right at the dye front when using a 5% polyacrylamide gel. (**C**) Immunoprecipitation of D1*N-E3\_*D4 after cell surface biotinylation in four independent assays. Input samples represents the whole cell lysate, IP samples represents the immunoprecipitated proteins. D1*N-E3\_*D4 is detected in IP samples indicating its presence at the cell surface. The expression, however, cannot be quantified with confidence as the proteins are detected right at the dye front when using a 5% polyacrylamide gel. Pink arrowheads point to the proteins of interest. Green rectangles highlight the D1*N-E3\_*D4 chimera lysate in (**A**) and (**B**).](elife-40045-resp-fig1){#respfig1}

> 13\) The chimeric ligand is expressed more efficiently than the endogenous one (Figure 3C). Could this affect the result?

We appreciate the reviewer's concern about whether there are different amounts of protein in the two conditions. However, because anti-DLL1 antibodies were used to detect endogenous DLL1, and anti-DLL4 antibodies to detect the chimeric ligand (as indicated in the panels of Figure 3C), which cannot be detected using the anti-DLL1 antibodies, the protein levels cannot be compared based on differences in staining intensity because the antibodies are different.

In addition, we have corrected spelling/formatting mistakes and errors, updated legends and references to figures, figure supplements and source data files, included the Key Resources Table and a statement concerning mycoplasma tests and cell line authentication in the Materials and methods section, and made other changes requested by the editorial support team (supplementary files changed to figure supplements, file type changes, adjustment of nomenclature, added information in the Materials and methods section).

[^1]: Evidera, Waltham, United State.
